

PRODUCT MONOGRAPH

Pr **GEMZAR**[®]

Gemcitabine Hydrochloride for Injection

200 mg or 1 g gemcitabine per vial

Antineoplastic Agent

© Eli Lilly Canada
3650 Danforth Ave.
Toronto, Ontario
M1N 2E8
1-888-545-5972
www.lilly.ca

Date of Revision:
February 02, 2006

Submission Control No. 102949

[®] GEMZAR is a registered trademark of Eli Lilly and Company

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	7
DRUG INTERACTIONS	20
DOSAGE AND ADMINISTRATION	20
OVERDOSAGE	24
ACTION AND CLINICAL PHARMACOLOGY	24
STORAGE AND STABILITY	25
DOSAGE FORMS, COMPOSITION AND PACKAGING	26
PART II: SCIENTIFIC INFORMATION	27
PHARMACEUTICAL INFORMATION.....	27
CLINICAL TRIALS.....	28
DETAILED PHARMACOLOGY	41
TOXICOLOGY	42
REFERENCES	47
PART III: CONSUMER INFORMATION.....	52

GEMZAR[®]

Gemcitabine Hydrochloride for Injection

200 mg or 1 g gemcitabine per vial

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients*
Intravenous	200 mg and 1 g vial	mannitol and sodium acetate

* For a complete listing see Dosage Forms, Composition and Packaging section.

INDICATIONS AND CLINICAL USE

GEMZAR is indicated for the:

- Treatment of patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas to achieve a Clinical Benefit Response (a composite measure of clinical improvement).
- Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) as either a single agent or in combination with cisplatin.
- Treatment of patients with Stage IV (locally advanced or metastatic) transitional cell carcinoma (TCC) of the bladder in combination with cisplatin.
- Treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer, who have good performance status and have relapsed following adjuvant anthracycline-based chemotherapy.

GEMZAR should be used only under the supervision of a qualified healthcare professional who is experienced in the use of chemotherapeutic agents and in the management of patients with cancer. Appropriate management of therapy and complications is only possible when adequate diagnostic and treatment facilities are readily available.

Geriatrics (> 65 years of age):

GEMZAR has been well tolerated in patients over the age of 65. Although clearance is affected by age (see ACTION AND CLINICAL PHARMACOLOGY section), there is no evidence that further dose adjustments, (i.e. other than those already recommended in the DOSAGE AND ADMINISTRATION section) are necessary in patients over the age of 65.

Pediatrics (< 17 years of age):

Safety and effectiveness in children have not been established.

CONTRAINDICATIONS

GEMZAR is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.

WARNINGS AND PRECAUTIONS**Serious Warnings and Precautions**

- GEMZAR is a cytotoxic drug and should be used only by physicians experienced with chemotherapeutic drugs. Patients should be informed of the risks associated with GEMZAR therapy.
- Prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing have been shown to increase toxicity (see DOSAGE AND ADMINISTRATION; and Part II: CLINICAL TRIALS sections).
- GEMZAR should be used with extreme caution in patients whose bone marrow reserve may have been compromised by prior irradiation or chemotherapy, or whose marrow function is recovering from previous chemotherapy.
- GEMZAR can suppress bone marrow function manifested by leucopenia, thrombocytopenia and anemia. Patients should be closely monitored prior to each dose for granulocyte and platelet counts. The dosage should be reduced, omitted, or the drug discontinued upon evidence of abnormal suppression of the bone marrow (see DOSAGE AND ADMINISTRATION section).
- Periodic physical examination and checks of renal and hepatic function should be made to detect non-hematologic toxicity. Doses may be reduced or withheld based upon the level of toxicity.
- Administration of GEMZAR in patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis may lead to exacerbation of the underlying hepatic insufficiency (see DOSAGE AND ADMINISTRATION section).
- Acute shortness of breath with a temporal relationship to GEMZAR administration may occur (see ADVERSE REACTIONS; and DOSAGE AND ADMINISTRATION sections).
- This preparation is for intravenous administration only.

General

In all instances where the use of GEMZAR is considered for chemotherapy, the physician must evaluate the need and usefulness of the drug against the risk of adverse events. If severe adverse events occur, the drug should be reduced in dosage, omitted, or discontinued

and appropriate corrective measures should be taken based on the clinical judgement of the physician (see DOSAGE AND ADMINISTRATION section).

Most drug-related adverse reactions observed with GEMZAR therapy are reversible (see ADVERSE REACTIONS section).

Cardiovascular

Heart failure has been reported very rarely (<0.01%). Arrhythmias, predominantly supraventricular in nature, have been reported signaling awareness of the possibility of cardiovascular events (see ADVERSE REACTIONS: Clinical Trial Adverse Drug Reactions and Post-Market Adverse Drug Reactions sections).

Carcinogenesis and Mutagenesis

Information available is based upon preclinical studies (see TOXICOLOGY section).

Fever and Flu-Like Symptoms

GEMZAR may cause fever, with or without flu-like symptoms, in the absence of clinical infection (see ADVERSE REACTIONS section). The administration of acetaminophen may provide symptomatic relief.

Hematologic

GEMZAR can suppress bone marrow function as manifested by leukopenia, thrombocytopenia and anemia. Blood counts should be taken prior to each dose (see DOSAGE AND ADMINISTRATION section for dose reduction guidelines).

Hepatic

Cases of serious hepatotoxicity including liver failure and death have been very rarely reported in patients receiving GEMZAR alone or in combination with other potentially hepatotoxic drugs. A causal relationship between GEMZAR and severe hepatotoxicity including liver failure and death has not been established (see WARNINGS AND PRECAUTIONS: Special Populations; ADVERSE REACTIONS: Clinical Trial Adverse Drug Reactions and Post-Market Adverse Drug Reactions sections).

Radiosensitizing Effect

In a single trial where GEMZAR at a dose of 1000 mg/m² was administered once weekly for up to six (6) consecutive weeks concurrently with therapeutic thoracic radiation to patients with NSCLC, significant toxicity was observed in the form of severe, and potentially life-threatening mucositis, especially esophagitis and pneumonitis, particularly in patients receiving large volumes of radiotherapy [median treatment volumes 4,795 cm³] (see DRUG INTERACTIONS section for more information). The optimum regimen for safe administration of GEMZAR with therapeutic doses of radiation has not yet been determined.

Renal

There have been cases of histologically confirmed Hemolytic Uremic Syndrome (HUS) reported in patients treated with GEMZAR. Renal failure leading to death or requiring dialysis despite discontinuation of therapy has been reported rarely. The majority of cases of renal failure leading to death were due to HUS (see WARNINGS AND PRECAUTIONS:

Special Populations; ADVERSE REACTIONS: Clinical Trial Adverse Drug Reactions and Post-Market Adverse Drug Reactions sections).

GEMZAR should be discontinued at the first signs of any evidence of microangiopathic hemolytic anemia such as rapidly falling hemoglobin with concomitant thrombocytopenia, elevation of serum bilirubin, serum creatinine, blood urea nitrogen, or LDH. Renal failure may not be reversible even with discontinuation of therapy, and dialysis may be required.

Respiratory

Acute shortness of breath in association with GEMZAR administration may occur. Bronchodilators, corticosteroids, and/or oxygen produce symptomatic relief.

Pulmonary effects, sometimes severe (such as pulmonary edema, interstitial pneumonitis, or adult respiratory distress syndrome (ARDS)) have been reported rarely (<0.1%) in association with GEMZAR therapy. The etiology of these effects is unknown. If such effects develop, patients should discontinue therapy with GEMZAR and not be re-challenged with the drug. See ADVERSE REACTIONS: Pulmonary; and DOSAGE AND ADMINISTRATION sections.

Skin

GEMZAR administration has been associated with rash (see ADVERSE REACTIONS). Topical corticosteroids may provide symptomatic relief.

Severe skin reactions, including desquamation and bullous skin eruptions such as toxic epidermal necrolysis (TEN) and Stevens Johnson syndrome (SJS), have been reported very rarely (<0.01%).

Vascular

Clinical signs of peripheral vasculitis and gangrene have been reported very rarely (<0.01%) in association with GEMZAR therapy.

Special Populations

Gender: GEMZAR clearance is affected by gender (see ACTION AND CLINICAL PHARMACOLOGY section). There is no evidence, however, that further dose adjustments (i.e. other than those already recommended in the DOSAGE AND ADMINISTRATION section) are necessary in women.

Renal and Hepatic Impairment: GEMZAR should be used with caution in patients with pre-existing renal or hepatic insufficiency, as there is insufficient information from clinical studies to allow clear dose recommendations for this patient population. All combination studies involving GEMZAR and cisplatin have been performed in patients with creatinine clearance of ≥ 60 mL/minute.

Administration of GEMZAR in patients with compromised liver function due to liver metastasis or a pre-existing medical history of hepatitis, alcoholism, or liver cirrhosis may lead to exacerbation of the underlying hepatic insufficiency (see DOSAGE AND ADMINISTRATION sections).

Pregnant Women: The use of GEMZAR should be avoided in pregnant women because of the potential hazard to the fetus. Evaluation of experimental animal studies has shown reproductive toxicity, e.g. birth defects or other effects on the development of the embryo or fetus, the course of gestation or peri-and postnatal development.

Nursing Women: The use of GEMZAR should be avoided in nursing women because of the potential hazard to the infant.

Pediatrics (< 17 years of age): Safety and effectiveness in children have not been established.

Geriatrics (> 65 years of age): GEMZAR has been well tolerated in patients over the age of 65. Although clearance is affected by age (see ACTION AND CLINICAL PHARMACOLOGY section), there is no evidence that further dose adjustments, (i.e. other than those recommended under Dosage and Administration) are necessary in patients over the age of 65.

ADVERSE REACTIONS

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

GEMZAR (gemcitabine hydrochloride) has been used, both as a single agent and in combination with other cytotoxic drugs.

Single-Agent Use: Data in Table 1 are based on 22 clinical studies (N=979) of GEMZAR administered as a single agent, using starting doses in the range of 800 to 1250 mg/m² administered weekly as a 30-minute infusion for the treatment of a wide variety of malignancies. Of the 979 patients only 10.4% (102) were discontinued due to an adverse event regardless of causality. WHO grade 3 or 4 toxicity of non-laboratory events, was less than 1% for all parameters except nausea and vomiting, pulmonary toxicity, infection and pain.

All WHO-graded laboratory toxicities for a total of 979 patients are listed in Table 1, regardless of causality. Non-laboratory WHO-toxicities were available for 565 patients. They are listed in Table 1 (for parameters that occurred in ≥5% of patients), or discussed below. Edema, extravasation and flu-like symptoms were reported regardless of causality as treatment emergent signs and symptoms (TESS¹; N=979).

¹ TESS: An event was considered treatment-emergent, if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is important to emphasize that although the events were reported during therapy, they were not necessarily caused by the therapy.

Data are also shown (Table 1) for the subset of patients (N=360) with non-small cell lung cancer treated in 4 clinical studies (2 studies WHO laboratory toxicities; 2 studies non-laboratory WHO-toxicities) and the subset of patients (N=159) with pancreatic cancer treated in 5 clinical studies (WHO laboratory and non-laboratory toxicities). The frequency of all grades were generally similar for the overall safety database and the subsets of patients with non-small cell lung cancer and pancreatic cancer.

Table 1: WHO-Graded Toxicities occurring with a $\geq 5\%$ frequency in Patients Receiving GEMZAR

WHO Grades (in % frequency) are rounded to the closest integer										
	All Patients			Non Small Cell Lung Cancer Patients			Pancreatic Cancer Patients			Discontinuations (%)
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4	All Patients
LABORATORY	(N=979)			(N=360)			(N=244)			(N=979)
Hematologic										
Anemia	68	7	1	65	5	<1	73	8	3	<1
Neutropenia	63	19	6	61	20	5	61	17	7	
Leukopenia	62	9	<1	55	7	<1	63	8	1	<1
Thrombocytopenia	24	4	1	16	1	1	36	7	<1	<1
Hepatic										
ALT	68	8	2	70	9	3	72	10	1	<1
AST	67	7	2	67	5	1	78	12	5	
Alkaline Phosphatase	55	7	2	48	2	0	77	16	4	
Bilirubin	13	2	<1	8	<1	<1	26	6	3	
Renal										
Proteinuria	36	<1	0	52	<1	0	15	<1	0	
Hematuria	31	<1	0	43	2	0	14	0	0	
BUN	16	0	0	16	0	0	15	0	0	<1
Creatinine	7	<1	0	6	<1	0	6	0	0	
NON-LABORATORY	(N=565)			(N=243)			(N=159)			(N=979)
Gastrointestinal Disorders										
Nausea and Vomiting	64	17	1	69	19	<1	62	12	2	<1
Diarrhea	12	<1	0	6	<1	0	24	2	0	0
Constipation	8	<1	0	7	<1	0	13	2	0	0
Stomatitis	8	<1	0	7	<1	0	10	0	0	<1
General Disorders and Administration Site Conditions										
Fever	37	<1	0	46	<1	0	28	<1	0	<1
Pain	16	1	0	16	1	0	12	2	0	<1
Infections										
Infection	9	1	<1	10	0	0	8	1	0	<1
Nervous System Disorders										
State of Consciousness/Somnolence	9	<1	0	6	0	0	10	3	0	<1

Table 1: WHO-Graded Toxicities occurring with a $\geq 5\%$ frequency in Patients Receiving GEMZAR (Cont'd)

WHO Grades (in % frequency) are rounded to the closest integer										
	All Patients			Non Small Cell Lung Cancer Patients			Pancreatic Cancer Patients			Discontinuations (%)
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4	All Patients
Respiratory Disorders										
Dyspnea	8	1	<1	8	2	0	6	0	0	<1
Skin and Subcutaneous Tissue Disorders										
Skin Rash	25	<1	0	30	0	0	22	0	0	<1
Alopecia	14	<1	0	14	<1	0	14	0	0	0

Grade based on criteria from the World Health Organization (WHO)

Alopecia:

Hair loss (alopecia), usually minimal, was reported for any WHO grade in only 13.7% of patients. No grade 4 toxicity (non-reversible alopecia) was reported, and only 0.4% of patients reported grade 3 toxicity (complete but reversible alopecia).

Cardiac Toxicity:

Less than two percent of patients discontinued therapy with GEMZAR due to cardiovascular events such as myocardial infarction, arrhythmia, chest pain, heart failure, pulmonary edema and hypertension. Many of these patients had a prior history of cardiovascular disease.

Cutaneous Toxicity:

A rash was seen in 24.8% of patients, was usually mild, not dose limiting and responded to local therapy (see WARNINGS AND PRECAUTIONS section). The rash was typically a macular or finely granular maculopapular pruritic eruption of mild to moderate severity involving the trunk and extremities.

Edema:

The occurrence of Edema is reported regardless of causality, as a treatment emergent event (TESS). Edema (13%), peripheral edema (20%) and facial edema (<1%) were reported. Overall, edema was usually mild to moderate and reversible. Less than 1% of patients (N=979) discontinued due to edema.

Extravasation:

GEMZAR is well tolerated during the infusion with only a few cases (4%) of injection site reaction reported. GEMZAR does not appear to be a vesicant (see DOSAGE AND ADMINISTRATION section). There have been no reports of injection site necrosis.

Fever and Infection:

Fever of any severity was reported in 37.3% of patients. Fever was frequently associated with other flu-like symptoms and was usually mild and clinically manageable. Less than 1% of patients were discontinued for fever. The incidence of fever contrasts with the incidence

of infection (8.7%) and indicates that GEMZAR may cause fever in the absence of clinical infection (see WARNINGS AND PRECAUTIONS section).

Flu-Like Symptoms:

“Flu-syndrome” was reported regardless of causality (TESS) for 18.9% of patients (N=979). Individual symptoms of headache, anorexia, fever, chills, myalgia and asthenia were the most commonly reported symptoms. Cough, rhinitis, malaise, sweating and insomnia were also commonly reported. Less than 1% of patients discontinued due to flu-like symptoms.

Gastrointestinal:

Mild or moderate nausea and vomiting (WHO toxicity grade 1 and 2) was reported in 64% of all patients. WHO grade 3 toxicity, defined as vomiting requiring therapy, was reported in 17.1% of patients. Any patient who received prophylactic antiemetics, was automatically graded \geq WHO grade 3, even if they only developed mild nausea. Diarrhea and stomatitis were usually mild and occurred in less than 13% of patients. WHO toxicity for constipation was mild (WHO grade 1) in the majority of cases and was reported for 7.8% of patients.

Hematologic:

Myelosuppression is the major dose-limiting toxicity with GEMZAR; it was usually of short duration, reversible and not cumulative over time. Less than 1% of patients discontinued therapy for either anemia, leukopenia, or thrombocytopenia. Red blood cell transfusions were received by 19% of patients and less than 1% of patients received platelet transfusions. The incidence of major infection (WHO grade toxicity of 3) was only 1.1% and only one grade 4 toxicity for infection occurred.

Hepatic:

GEMZAR was associated with transient elevations of serum transaminases (predominantly WHO grades 1 and 2) in approximately two-thirds of patients, but there was no evidence of increasing hepatic toxicity with either longer duration of treatment with GEMZAR or with greater total cumulative dose.

Neurotoxicity:

WHO grade 1 or 2 peripheral neurotoxicity² was reported for 3.3% of patients. No patient reported WHO grade 3 or 4 toxicity.

State of consciousness toxicity was usually mild to moderate (WHO grades 1 and 2); somnolence was reported for 4.6% of patients.

Pulmonary and Allergic:

GEMZAR should not be administered to patients with a known hypersensitivity to this drug. One case of anaphylactoid reaction has been reported.

The administration of GEMZAR has been infrequently associated with shortness of breath (Dyspnea; See WARNINGS AND PRECAUTIONS section). Dyspnea when graded by

² WHO grade 1 peripheral neurotoxicity is defined as paresthesia and/or decreased tendon reflexes and WHO grade 2 toxicity is defined as severe paresthesia and /or mild weakness.

WHO-toxicity criteria (Table 1), was reported in 8%, and severe dyspnea (WHO grades 3 and 4) was reported in 1.4% of patients.

Dyspnea, regardless of causality (TESS) was reported in 23% of patients and serious dyspnea was reported in 3% of patients. It should be noted that in both of these analyses, the occurrence of dyspnea may have been due to underlying disease such as lung cancer (40% of study population) or pulmonary manifestations of other malignancies. Dyspnea was occasionally accompanied by bronchospasm (<1% of patients).

Renal:

Mild proteinuria and hematuria were commonly reported. Clinical findings consistent with the hemolytic uremic syndrome (HUS) were reported in 6 out of 2429 patients (0.25%) receiving GEMZAR in clinical trials (see WARNINGS AND PRECAUTIONS section). Renal failure associated with HUS, may not be reversible even with discontinuation of therapy and dialysis may be required.

Combination Use with Cisplatin in Non-Small Cell Lung Cancer: This section focuses on adverse events that were increased in frequency and/or severity with the addition of cisplatin to GEMZAR. GEMZAR plus cisplatin was compared to single-agent cisplatin in a randomized trial, and safety data were collected using NCI Common Toxicity Criteria (CTC). In a second randomized trial, GEMZAR plus cisplatin was compared to the combination of cisplatin plus etoposide, and World Health Organization (WHO) criteria were used to grade adverse reactions. All CTC- and WHO-graded adverse events that occurred in $\geq 10\%$ of patients are listed in Table 2. Toxicity grades for laboratory parameters are reported regardless of causality.

Table 2: CTC- and WHO-Graded Toxicities occurring with a $\geq 10\%$ frequency in NSCLC Patients Receiving GEMZAR plus Cisplatin

CTC and WHO Grades (in % frequency) are rounded to the closest integer							
NCI COMMON TOXICITY CRITERIA	GEMZAR plus Cisplatin (n=260) ^a vs. Cisplatin (n=262) (% incidence)			WORLD HEALTH ORGANIZATION CRITERIA	GEMZAR plus Cisplatin (n=69) ^b vs. Cisplatin plus Etoposide (n=66) (% incidence)		
	All Grades	Grade 3	Grade 4		All Grades	Grade 3	Grade 4
LABORATORY^c							
Hematologic							
Anemia	89	22	3	Anemia	88	22	0
Thrombocytopenia	85	25	25	Thrombocytopenia	81	39	16
Leukopenia	82	35	11	Leukopenia	86	26	3
Neutropenia	79	22	35	Neutropenia	88	36	28
Lymphocytes	75	25	18				
Hepatic							
Transaminase	22	2	1				
Alkaline Phosphatase	19	1	0	Alkaline Phosphatase	16	0	0

Table 2: CTC- and WHO-Graded Toxicities occurring with a $\geq 10\%$ frequency in NSCLC Patients Receiving GEMZAR plus Cisplatin (Cont'd)

Renal							
Creatinine	38	4	<1				
Proteinuria	23	0	0	Proteinuria	12	0	0
Hematuria	15	0	0	Hematuria	22	0	0
Other Laboratory							
Hypomagnesemia	30	4	3				
Hyperglycemia	30	4	0				
Hypocalcemia	18	2	0				
NON-LABORATORY^d							
Blood							
Hemorrhage	14	1	0				
Gastrointestinal Disorders							
Nausea	93	25	2	Nausea and Vomiting	96	35	4
Vomiting	78	11	12				
Constipation	28	3	0	Constipation	17	0	0
Diarrhea	24	2	2	Diarrhea	14	1	1
Stomatitis	14	1	0	Stomatitis	20	4	0
General Disorders and Administration Site Conditions							
Fever	16	0	0				
Local	15	0	0				
Infections							
Infections	18	3	2	Infection	28	3	1
Nervous System Disorders							
Neuro-Motor	35	12	0	Paresthesias	38	0	0
Neuro-Hearing	25	6	0				
Neuro-Sensory	23	1	0				
Neuro-Cortical	16	3	1				
Neuro-Mood	16	1	0				
Neuro-Headache	14	0	0				
Respiratory Disorders							
Dyspnea	12	4	3				
Skin and Subcutaneous Tissue Disorders							
Alopecia	53	1	0	Alopecia	77	13	0
Rash	11	0	0	Rash	10	0	0
Vascular Disorders							
Hypotension	12	1	0				

^a GEMZAR plus cisplatin patients with laboratory or non-laboratory data, N=217-253. GEMZAR at 1000 mg/m² on Days 1, 8, and 15, and cisplatin at 100 mg/m² on Day 1 every 28 days.

^b GEMZAR plus cisplatin patients with laboratory or non-laboratory data, N=67-69. GEMZAR at 1250 mg/m² on Days 1 and 8, and cisplatin at 100 mg/m² on Day 1 every 21 days.

^c Regardless of causality.

^d Non-laboratory events were graded only if assessed to be possibly drug-related.

Alopecia:

In comparison with single-agent GEMZAR therapy, the incidence of alopecia with GEMZAR plus cisplatin combination therapy was increased; 14% with GEMZAR alone versus 53% and 77% with GEMZAR plus cisplatin. Hair loss was usually minimal (CTC/WHO Grade 1 or 2).

However, 0.8% of patients that received GEMZAR plus cisplatin on the 4-week schedule experienced CTC Grade 3 alopecia, and 13% of patients who were on the 3-week schedule experienced WHO Grade 3 alopecia. No irreversible (i.e. Grade 4) hair loss was reported.

Fever and Infection:

The majority of patients that received GEMZAR plus cisplatin did not develop fever and only one patient (4-week cycle) experienced CTC Grade 3 fever. On the 4-week GEMZAR plus cisplatin schedule, CTC Grade 3 and 4 infection was seen in 2.8% and 1.6% of patients, respectively. On the 3-week schedule, WHO Grade 3 and 4 infection was seen in 2.9% and 1.4% of patients, respectively.

Gastrointestinal:

The incidence of nausea and vomiting was higher for combination therapy with GEMZAR plus cisplatin (~90%) than it was for single agent GEMZAR (50-70%). On the 4 week cycle, 23% of patients in the GEMZAR plus cisplatin arm experienced CTC Grade 3 or Grade 4 nausea and vomiting, and on the 3 week cycle, the incidence of WHO Grade 3 or 4 nausea and vomiting was 39.1% in the GEMZAR plus cisplatin arm, despite the use of antiemetics. Although nausea and vomiting were frequent, they were rarely dose-limiting and were seldom reasons for discontinuation from the study. Diarrhea, stomatitis and constipation were usually mild and occurred in 14-28% of patients that received GEMZAR plus cisplatin.

Hematologic:

As expected, myelosuppression occurred more frequently with GEMZAR plus cisplatin treatment (~90%) than with GEMZAR monotherapy (~60%), and GEMZAR dosage adjustments for hematologic toxicity were required more often with combination therapy. Although myelosuppression was common, early study discontinuation due to bone marrow suppression occurred in only 3.1% and 4.3% of patients receiving GEMZAR plus cisplatin in the two randomized trials. Platelet transfusions were required by 3% and 21% of patients that received GEMZAR plus cisplatin on a 3-week or 4-week cycle, respectively, and red blood cell transfusions were required by approximately 30-40% of patients. Less than 8% of patients treated with GEMZAR plus cisplatin were hospitalized for febrile neutropenia. Sepsis and severe hemorrhagic events were rare.

Neurotoxicity:

CTC Grade 3 neurohearing toxicity (hearing loss interfering with function but correctable with hearing aid) was experienced by 5.6% and 2.9% of GEMZAR plus cisplatin patients on 4-week and 3-week schedules, respectively. CTC Grade 3 neuromotor toxicity was experienced by 11.5% of GEMZAR plus cisplatin patients on the 4-week schedule, and 38% of patients on the 3-week schedule experienced peripheral neurotoxicity (WHO Grade 1 or 2 only).

Renal:

On the 4-week GEMZAR plus cisplatin schedule, CTC Grade 3 creatinine toxicity was observed in 4.4% of patients, and one patient experienced Grade 4 creatinine toxicity. On the 3-week schedule, no WHO Grade 2, 3 or 4 BUN or creatinine toxicity were observed.

Combination Use with Cisplatin in Bladder Cancer [Transitional Cell Carcinoma (TCC) of the Urothelium]: The following information presents adverse events seen with GEMZAR in combination with cisplatin for treatment of bladder cancer. GEMZAR plus cisplatin (GC) was compared to MVAC in a pivotal, randomized trial.

Safety data were collected using the WHO toxicity criteria with the exception of Neuro Hearing event which was graded using the NCI Common Toxicity Criteria. All WHO- and CTC graded adverse events that occurred in $\geq 10\%$ of patients are listed in Table 3.

Alopecia:

Grade 3 and 4 alopecia occurred significantly less often in GEMZAR plus cisplatin patients than in MVAC patients (GC 10.5% vs. 55.2%).

Cardiac:

Grade 3 and 4 cardiovascular events such as myocardial function, arrhythmia, chest pain, heart failure, pulmonary edema and hypertension were rare; Grade 3 events occurred in 4.1% of patients on GEMZAR plus cisplatin. There were no Grade 4 events. In the MVAC arm 2.2% of patients experienced Grade 3 events and 0.5% of patients experience Grade 4 events.

Gastrointestinal:

The incidence of diarrhea was higher in the MVAC treatment arm than it was for the GEMZAR plus cisplatin. In the MVAC arm, 8% of patients experienced Grade 3 or 4 diarrhea compared to 3% of patients in the GEMZAR plus cisplatin arm. Nausea and vomiting occurred in similar frequencies among the GEMZAR plus cisplatin (22%) and the MVAC arms (21%).

Hematologic:

Hematologic toxicity was the most frequent laboratory toxicity seen on both treatment arms in this pivotal trial. Grade 3 and 4 neutropenia occurred less often in GEMZAR plus cisplatin patients than in MVAC patients (GC 71% vs. MVAC 82%). Grade 3 and 4 anemia was more common on the GEMZAR plus cisplatin arm versus MVAC arm (27% vs. 18%). Grade 3 and 4 thrombocytopenia was more common on the GEMZAR plus cisplatin arm versus MVAC arm (GC 57% vs. MVAC 21%). In patients with Grade 3 or 4 thrombocytopenia there was no Grade 4 bleeding and only infrequent Grade 3 bleeding (<2%) on either arm. On the GEMZAR plus cisplatin arm, for every 100 cycles of chemotherapy, 13 patients received whole blood or red blood cell transfusion. On the MVAC arm, for every 100 cycles of chemotherapy, 13 patients received whole blood or red blood cell transfusion. On the GEMZAR plus cisplatin arm, for every 100 cycles of chemotherapy, 4 patients received platelet transfusion. On the MVAC arm, for every 100 cycles of chemotherapy, 2 patients received platelet transfusion.

Neurotoxicity:

Of the 191 patients assessed in the GEMZAR plus cisplatin arm, CTC Grade 3 neurohearing toxicity occurred in 3 patients (2%). No patient experienced Grade 4 neurohearing toxicity.

By comparison, out of 173 patients assessed in the MVAC arm, CTC Grade 3 neurohearing toxicity occurred in 3 patients. Grade 4 neurohearing toxicity occurred in 1 patient.

Pulmonary:

Grade 3 and 4 dyspnea occurred in 2.5% and 0.5% of patients on the GEMZAR plus cisplatin respectively, while compared to 2.6% Grade 3 and 3.1% Grade 4 dyspnea in the MVAC arm.

Renal:

No patients on the GEMZAR plus cisplatin arm experienced Grade 3 or 4 renal toxicity, while Grade 3 renal toxicity was observed in 0.5% of patients in the MVAC arm. Renal toxicity was measured by serum creatinine levels.

Table 3: Selected WHO-Graded Adverse Events from Comparative Trial of GEMZAR plus Cisplatin versus MVAC in TCC of the Bladder

WHO Grades (% incidence)						
	GEMZAR plus Cisplatin ^a			MVAC ^b		
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4
LABORATORY^c						
Hematologic						
Anemia	94	24	4	86	16	2
Leukopenia	92	44	7	93	46	18
Neutropenia	91	41	30	89	17	65
Thrombocytopenia	86	29	29	46	8	13
Platelet Transfusions ^d	18			8		
Hepatic						
AST	30	1	0	28	2	0
ALT	29	1	0	28	2	0
Alkaline Phosphatase	17	2	1	19	1	0
Renal						
BUN	36	1	0	37	0	0
Creatinine	24	0	0	23	1	0
Hematuria	18	5	0	21	2	0
Proteinuria	9	0	0	14	1	0
NON-LABORATORY^e						
Blood						
Hemorrhage	23	2	0	15	2	0
Gastrointestinal Disorders						
Nausea and Vomiting	78	22	0	86	19	2
Constipation	38	2	0	39	3	1
Diarrhea	24	3	0	34	8	1
Stomatitis	20	1	0	66	18	4
General Disorders and Administration Site Conditions						
Fever	21	0	0	30	3	0
Infections						
Infection	24	2	1	47	10	5
Nervous System Disorders						
Paresthesias	26	1	0	25	1	0
Neuro-Hearing ^f	19	2	0	14	2	1
Somnolence	17	1	0	30	3	1

Table 3: Selected WHO-Graded Adverse Events from Comparative Trial of GEMZAR plus Cisplatin versus MVAC in TCC of the Bladder (Cont'd)

Respiratory Disorders						
Dyspnea	28	3	1	21	3	3
Skin						
Alopecia	61	11	0	89	54	1
Rash	23	0	0	16	0	1

Grade based on criteria from the World Health Organization (WHO)

- ^a N=191-200; all patients on GEMZAR plus cisplatin with laboratory or non-laboratory data; GEMZAR 1000 mg/m² on Days 1, 8, and 15, and cisplatin 70 mg/m² on Day 2 of each 28-day cycle
- ^b N=186-194; all patients on MVAC with laboratory or non-laboratory data: methotrexate 30 mg/m² on Days 1, 15, and 22, vinblastine 3 mg/m² on Days 2, 15, and 22, doxorubicin 30 mg/m² on Day 2, and cisplatin 70 mg/m² on Day 2 of each 28-day cycle
- ^c Regardless of causality
- ^d Percent of patients requiring transfusion
- ^e Non-laboratory events were graded only if assessed to be possibly treatment-related
- ^f Grade based on NCI Common Toxicity Criteria

Combination Use with Paclitaxel in Breast Cancer:

The following information presents adverse events seen with GEMZAR in combination with paclitaxel for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following anthracycline-based chemotherapy. GEMZAR plus paclitaxel was compared to paclitaxel in Study JHQG, an unblinded, multicentre, randomized Phase 3 study.

In the GEMZAR plus paclitaxel arm, 7% of patients discontinued treatment because of an adverse event compared to 5% on the paclitaxel arm. In the GEMZAR plus paclitaxel arm, 7% of GEMZAR doses were omitted and 8% were reduced, and 0.9% of paclitaxel doses were omitted and 5% were reduced. In the paclitaxel alone arm, 0.1% of paclitaxel doses were omitted and 2% were reduced. There were 12 deaths in the GEMZAR plus paclitaxel arm, and 8 in the paclitaxel alone arm on study or within 30 days after study drug discontinuation. One death on each arm of the study was possibly drug-related, while the rest of the deaths were attributed to progressive disease and a single death attributed to a traffic accident.

The hospitalization of patients in the GEMZAR plus paclitaxel arm and in the paclitaxel alone arm were similar and not statistically significant (8.8 % and 7.3%, respectively). Median number of cycles given in the GEMZAR plus paclitaxel arm was 6, compared with 5 cycles given in the paclitaxel alone arm.

Table 4 presents a summary of Grade 3 and 4 toxicities reported in the pivotal clinical study JHQG.

Table 4. Percentages of Patients with Grade 3 and 4 Toxicities Reported in the Clinical Study of GEMZAR in Combination with Paclitaxel in Patients with Metastatic Breast Cancer

	CTC Grades (% incidence, rounded to the closest integer) ^a					
	GEMZAR plus Paclitaxel (N=262)			Paclitaxel alone (N=259)		
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4
LABORATORY ^b						
Hematologic Events						
Neutropenia	69	31	17	31	4	7
Anemia	69	6	1	51	3	<1
Thrombocytopenia	26	5	<1	7	<1	<1
Leukopenia	21	10	1	12	2	0
Liver Abnormalities						
ALT	18	5	<1	6	<1	0
AST	16	2	0	5	<1	0
Metabolic						
Hyperglycemia	6	3	0	5	3	0
NON-LABORATORY ^c						
Cardiac Disorders						
Arrhythmia	<1	<1	0	0	0	0
Gastrointestinal Disorders						
Nausea	50	1	0	31	2	0
Vomiting	29	2	0	15	2	0
Diarrhea	20	3	0	13	2	0
Stomatitis / Pharyngitis	13	1	<1	8	<1	0
General Disorders						
Fatigue	40	6	<1	28	1	<1
Febrile neutropenia (drug-related)	6	5	<1	2	1	0
Immune System Disorder						
Allergic reaction / Hypersensitivity	5	0	0	3	<1	0
Musculoskeletal and Connective tissue Disorders						
Myalgia	33	4	0	33	3	<1
Arthralgia	24	3	0	22	2	<1
Peripheral Nervous System Disorders						
Neuropathy – sensory	64	5	<1	58	3	0
Neuropathy – motor	15	2	<1	10	<1	0
Respiratory Disorders						
Dyspnea	9	2	<1	3	0	0
Hypoxia	<1	0	0	<1	<1	0
Skin						
Alopecia	90	14	4	92	19	3

^a The toxicities above are as measured by the CTC scale, Version 2.0 (Study JHQQ).

^b Regardless of causality.

^c Non-laboratory events were graded only if assessed to be possibly drug-related.

Abbreviations: N = number of patients; ALT = alanine aminotransferase; AST = aspartate aminotransferase

Hematologic:

In Study JHQQ, more Grade 3 and 4 hematologic toxicities were reported with GEMZAR plus paclitaxel than paclitaxel alone. There was an increased incidence of red blood cell and/or whole blood transfusions (10% versus 4%), erythropoietin use (8% versus 3.5%), and granulocyte colony-stimulating factor use (7.6% versus 1.2%) in the GEMZAR plus paclitaxel arm than in the paclitaxel alone arm, respectively. There was a higher incidence of febrile neutropenia in the GEMZAR plus paclitaxel arm than in the paclitaxel alone arm (5% versus 1%; $p < 0.05$); however, there was not an increased incidence of Grade 3 and 4 infections (<1%) or hemorrhagic events (0%). Of the patients experiencing febrile neutropenia (5%) in the GEMZAR plus paclitaxel arm, the majority of patients required hospitalization and dose adjustments.

Hepatic:

Grade 3 and 4 liver enzyme elevation (ALT/AST) occurred in 8% of the patients treated with GEMZAR plus paclitaxel, and in 2% of the patients treated with paclitaxel alone.

Neurotoxicity:

Eleven patients in the GEMZAR plus paclitaxel arm and 4 patients in the paclitaxel alone arm discontinued study due to neuropathy. In the GEMZAR plus paclitaxel arm, the majority of patients with neuropathy reported the onset after Cycle 2, while in the paclitaxel alone arm, most patients with neuropathy reported the onset after Cycle 4. Nearly half of the patients on each treatment arm reported Grade 3 or 4 neuropathy that lasted for more than one cycle.

Pulmonary:

Grade 3 and 4 pulmonary toxicity characterized as dyspnea or hypoxia (2% versus <1%), were more common in the GEMZAR plus paclitaxel arm compared with the paclitaxel alone arm. Dyspnea was reported as worsening at the time of disease progression in patients who had this symptom reported at the time of study entry. All patients who reported dyspnea as Grade 3 or 4 toxicity and most who reported it as a serious adverse event had metastatic disease in the lungs and/or pleural effusion. No patients discontinued from the study because of grade 3 or 4 dyspnea.

Other Grade 3 or 4 Toxicities:

Grade 3 and 4 nonlaboratory toxicities were more common in the GEMZAR plus paclitaxel arm.

The incidence of Grade 3 and 4 fatigue was 6% in the GEMZAR plus paclitaxel arm and 2% in the paclitaxel alone arm ($p < 0.05$); however, there were no discontinuations due to Grade 3 or 4 fatigue. Grade 3 and 4 fatigue was reported for only one cycle in most patients on both treatment arms and was not associated with anemia.

Alopecia was common and was noted in both treatment arms (18% Grade 3/4 alopecia in the GEMZAR plus paclitaxel arm, and 22% Grade 3/4 alopecia in the paclitaxel alone arm).

Post-Market Adverse Drug Reactions

Cardiovascular:

Heart failure has been reported very rarely (<0.01%). Arrhythmias, predominantly supraventricular in nature, have been reported signaling awareness of the possibility of cardiovascular events.

Genito-Urinary System:

Clinical findings consistent with the hemolytic uremic syndrome (HUS) were rarely (<0.1%) reported in patients receiving GEMZAR. GEMZAR should be discontinued at the first signs of any evidence of microangiopathic hemolytic anemia such as rapidly falling hemoglobin with concomitant thrombocytopenia, elevation of serum bilirubin, serum creatinine, blood urea nitrogen, or LDH. Renal failure may not be reversible even with discontinuation of therapy, and dialysis may be required.

Hepatobiliary:

Increased liver function tests including elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase, and bilirubin levels have been reported rarely (<0.1%). These increases were not all transient, mild or non-progressive (see WARNINGS and PRECAUTIONS: Hepatic section).

Injury, Poisoning, and Procedural Complications:

Radiation toxicity and radiation recall reactions have been reported (see DRUG INTERACTIONS section).

Respiratory:

Pulmonary effects, sometimes severe (such as pulmonary edema, interstitial pneumonitis, or adult respiratory distress syndrome (ARDS)) have been reported rarely (<0.1%) in association with GEMZAR therapy. The etiology of these effects is unknown. If such effects develop, consideration should be given to discontinuing GEMZAR. Early use of supportive care measures may help ameliorate the condition.

Skin and Appendages:

Severe skin reactions, including desquamation and bullous skin eruptions, have been reported very rarely (<0.01%).

Vascular:

Clinical signs of peripheral vasculitis and gangrene have been reported very rarely (<0.01%).

DRUG INTERACTIONS

Overview

The radiosensitizing effects of GEMZAR are reviewed below.

Drug-Drug Interactions

Interactions with other drugs have not been established.

Drug-Food Interactions

Interactions with food have not been established.

Drug-Herb Interactions

Interactions with herbal products have not been established.

Drug-Laboratory Interactions

Interactions with laboratory tests have not been established.

Drug-Radiation Interactions

Concurrent radiotherapy (given together or ≤ 7 days apart): Toxicity associated with this multimodality therapy is dependent on many different factors, including dose of GEMZAR, frequency of gemcitabine administration, dose of radiation, radiotherapy planning technique, the target tissue, and target volume. Pre-clinical and clinical studies have shown that gemcitabine has radiosensitizing activity. In a single trial where GEMZAR at a dose of 1000 mg/m² was administered once weekly for up to six (6) consecutive weeks concurrently with therapeutic thoracic radiation to patients with NSCLC, significant toxicity was observed in the form of severe, and potentially life-threatening mucositis, especially esophagitis and pneumonitis, particularly in patients receiving large volumes of radiotherapy [median treatment volumes 4,795 cm³]. The optimum regimen for safe administration of GEMZAR with therapeutic doses of radiation has not yet been determined.

Radiation injury has been reported on targeted tissues (e.g. esophagitis, colitis, and pneumonitis) in association with both concurrent and non-concurrent use of GEMZAR. In addition, radiation recall has been seen with non-concurrent use.

DOSAGE AND ADMINISTRATION

Dosing Considerations

- This preparation is for intravenous use only.
- GEMZAR should be administered by healthcare professionals experienced in the administration of chemotherapeutic drugs.
- Patients should be monitored prior to each dose for granulocyte and platelet counts.
- Periodic physical examination and checks of renal and hepatic function should be made to detect non-hematologic toxicity.
- Dosage escalation or reduction should be based upon the degree of toxicities experienced by the patient.

Treatment Discontinuation

Acute shortness of breath in association with GEMZAR administration may occur. Bronchodilators, corticosteroids and/or oxygen produce symptomatic relief. Some reports of parenchymal lung toxicity were consistent with drug induced pneumonitis in association with the use of GEMZAR (see ADVERSE REACTIONS section). The mechanism of this toxicity is not known. Patients suspected of experiencing drug-induced pneumonitis should be discontinued and not be re-challenged with the drug.

Recommended Dose

Dosage - Pancreatic Cancer:

GEMZAR (gemcitabine hydrochloride) should be used by IV infusion at a dose of 1,000 mg/m² over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by one week of rest from treatment. Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out of every 4 weeks.

For dose adjustment guidelines, see Dose Adjustment: Dose Modifications for Pancreatic Cancer, Non-Small Cell Lung Cancer, and TCC of the Bladder Patients section below.

Dosage - Non-Small Cell Lung Cancer:

Single-agent GEMZAR should be administered by IV infusion at a dose of 1,000 mg/m² over 30 minutes once weekly for three consecutive weeks, followed by a one week rest period. This 4 week cycle is repeated.

GEMZAR has been given in combination with cisplatin on either a 4-week or a 3-week schedule. With the 4-week schedule, GEMZAR should be administered intravenously at 1000 mg/m² over 30 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin should be administered intravenously at 100 mg/m² on day 1 after the infusion of GEMZAR. With the 3-week schedule, GEMZAR should be administered intravenously at 1250 mg/m² over 30 minutes on days 1 and 8 of each 21-day cycle. Cisplatin at a dose of 100 mg/m² should be administered intravenously after the infusion of GEMZAR on day 1. See cisplatin prescribing information for administration and hydration guidelines.

For dose adjustment guidelines, see Dose Adjustment: Dose Modifications for Pancreatic Cancer, Non-Small Cell Lung Cancer, and TCC of the Bladder Patients section below.

Dosage - TCC of the Bladder:

GEMZAR should be administered by IV infusion at a dose of 1,000 mg/m² over 30 minutes on Days 1, 8 and 15 of each 28-day cycle. Cisplatin should be administered intravenously at 70 mg/m² on Day 1 of each 28-day cycle. This 4-week schedule is then repeated. See cisplatin prescribing information for administration and hydration guidelines. A clinical trial showed more myelosuppression when cisplatin was used in doses of 100 mg/m².

For dose adjustment guidelines, see Dose Adjustment: Dose Modifications for Pancreatic Cancer, Non-Small Cell Lung Cancer, and TCC of the Bladder Patients section below.

Dosage - Breast Cancer:

GEMZAR has been given in combination with paclitaxel. It is recommended to administer paclitaxel (175 mg/m²) on Day 1 over approximately 3 hours as an intravenous infusion, followed by GEMZAR (1250 mg/m²) as a 30-minute intravenous infusion on Days 1 and 8 of each 21-day cycle. Patients should have an absolute granulocyte count $\geq 1500 \times 10^6 /L$ and a platelet count $\geq 100,000 \times 10^6 /L$ prior to each cycle. See paclitaxel prescribing information for administration guidelines.

For dose adjustment guidelines, see Dose Adjustment: Dose Modifications for Breast Cancer Patients section below.

Dosage Adjustment

Dose Modifications for Pancreatic Cancer, Non-Small Cell Lung Cancer, and TCC of the Bladder Patients:

Patients receiving GEMZAR should be monitored prior to each dose for granulocyte and platelet counts and, if necessary, the dose of GEMZAR may be either reduced or withheld in the presence of hematological toxicity according to the guidelines in Table 5.

Table 5: Dose Adjustments Based on Granulocyte and Platelet Counts

Absolute granulocyte count ($\times 10^6/L$)		Platelet count ($\times 10^6/L$)	% of full dose
> 1,000	and	> 100,000	100
500 - 1000	or	50,000 – 100,000	75
< 500	or	< 50,000	hold

Periodic physical examination and checks of renal and hepatic function should be made to detect non-hematologic toxicity. Doses may be reduced or withheld based upon the level of toxicity.

Doses should be reduced or withheld until toxicity has resolved in the opinion of the physician.

Dose Modifications for Breast Cancer Patients:

Patients should be monitored prior to each dose with a complete blood count, including differential counts.

GEMZAR dosage adjustments for hematological toxicity are based on the granulocyte and platelet counts taken on Day 8 of therapy. If marrow suppression is detected, GEMZAR dosage should be modified according to the guidelines in Table 6.

Table 6: Day 8 Dosage Reduction Guidelines for GEMZAR in Combination with Paclitaxel.

Absolute granulocyte count ($\times 10^6/L$)		Platelet count ($\times 10^6/L$)	% of full dose
≥ 1200	and	> 75,000	100
1000 - 1199	or	50,000 - 75,000	75

700 - 999	and	≥ 50,000	50
< 700	or	< 50,000	hold

Periodic physical examination and checks of renal and hepatic function should be made to detect non-hematologic toxicity. Doses may be reduced or withheld based upon the level of toxicity.

Doses should be reduced or withheld until toxicity has resolved in the opinion of the physician.

For severe (Grade 3 or 4) non-hematological toxicity, therapy should be held or decreased by 50% depending on the judgement of the treating physician.

Administration

GEMZAR is well tolerated during the infusion, with only a few cases of injection site reaction reported. There have been no reports of injection site necrosis. GEMZAR also does not appear to act as a vesicant in a case of extravasation. GEMZAR may be administered on an outpatient basis.

As with other toxic compounds, caution should be exercised in handling and preparing solutions with GEMZAR. The use of gloves is recommended. If the solution of GEMZAR contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water or rinse the mucosa with copious amounts of water.

Reconstitution:

Vial Size	Volume of Diluent to be Added to Vial	Approximate Available Volume	Nominal Concentration per mL
200 mg	5.0 mL of 0.9% NaCl Injection	5 mL	38 mg/mL
1 g	25 mL of 0.9% NaCl Injection	25 mL	38 mg/mL

To reconstitute, add at least 5 mL of 0.9% Sodium Chloride Injection to the 200 mg vial or at least 25 mL of 0.9% Sodium Chloride Injection to the 1 g vial. Invert to dissolve. These dilutions each yield a GEMZAR concentration of 38 mg/mL. The appropriate amount of drug may be administered as prepared or further diluted with 0.9% Sodium Chloride Injection to concentrations as low as 0.1 mg/mL.

Reconstitution of concentrations greater than 40 mg/mL may result in incomplete dissolution, and should not be attempted.

Sterile isotonic saline (0.9% sodium chloride injection) without added preservatives should be used as a diluent.

Parenteral drugs should be inspected visually for particulate matter and discoloration, prior to administration, whenever solution and container permit.

See STORAGE AND STABILITY section for more details.

OVERDOSAGE

There is no known antidote for overdoses of GEMZAR (gemcitabine hydrochloride). Myelosuppression, and paresthesiae were the principal toxicities seen when a single dose as high as 5700 mg/m² was administered by IV infusion over 30 minutes every 2 weeks to several patients in a Phase I study. In the event of a suspected overdose, the patient should be monitored with appropriate blood counts and should receive supportive therapy, as necessary.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

GEMZAR (gemcitabine hydrochloride) is a cell-cycle dependent oncolytic agent of the “antimetabolite” class. It is a deoxycytidine analog (difluoro-deoxycytidine; dFdC) that is metabolized intracellularly to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effects of gemcitabine are exerted through dFdCDP-assisted incorporation of dFdCTP into DNA, resulting in inhibition of DNA synthesis and induction of apoptosis.

Pharmacokinetics

Gemcitabine disposition was studied in five patients who received a single 1000 mg/m²/30 minute infusion of radiolabeled drug. Within one (1) week, 92% to 98% of the dose was recovered, almost entirely in the urine. Gemcitabine (<10%) and the inactive uracil metabolite, 2'-deoxy-2',2'-difluorouridine (dFdU), accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma. Gemcitabine plasma protein binding is negligible.

The pharmacokinetics of gemcitabine were examined in 353 patients, about 2/3 men, with various solid tumours. Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given weekly with periodic rest weeks and using both short infusions (<70 minutes) and long infusions (70-285 minutes). The total gemcitabine dose varied from 500 to 3600 mg/m².

Gemcitabine pharmacokinetics are linear and are described by a 2-compartment model. Population pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of gemcitabine was significantly influenced by duration of infusion and gender. Clearance was affected by age and gender. Differences in either clearance or volume of distribution based on patient characteristics or the duration of infusion result in changes in half-life and plasma concentrations. Table 7 shows plasma clearance and half-life of gemcitabine following short infusions for typical patients by age and gender.

Table 7: Gemcitabine Clearance and Half-Life for the “Typical” Patient

Age	Clearance Men (L/hr/m ²)	Clearance Women (L/hr/m ²)	Half-Life ^a Men (min)	Half-Life ^a Women (min)
29	92.2	69.4	42	49
45	75.7	57.0	48	57
65	55.1	41.5	61	73
79	40.7	30.7	79	94

^a Half-life for patients receiving a short infusion (<70 min)

Gemcitabine half-life for short infusions ranged from 32 to 94 minutes, and the value for long infusions varied from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with longer infusions. The lower clearance in women and the elderly results in higher concentrations of gemcitabine for any given dose.

The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50 L/m² following infusions lasting <70 minutes, indicating that gemcitabine, after short infusions, is not extensively distributed into tissues. For long infusions, the volume of distribution rose to 370 L/m², reflecting slow equilibration of gemcitabine within the tissue compartment.

The maximum plasma concentrations of dFdU (inactive metabolite) were achieved up to 30 minutes after discontinuation of the infusions. The metabolite was excreted in urine without undergoing further biotransformation and did not accumulate with weekly dosing. Its elimination is dependent on renal excretion and the metabolite could accumulate with decreased renal function.

In patients with NSCLC or bladder cancer receiving combination therapy with gemcitabine plus cisplatin, the plasma concentrations of gemcitabine and its major metabolite, dFdU, did not differ significantly from those observed in patients receiving single-agent gemcitabine.

The effects of significant renal or hepatic insufficiency on the disposition of gemcitabine have not been assessed.

The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.

STORAGE AND STABILITY

GEMZAR should be stored in glass vials, at 15° to 30° C.

Parenteral drugs should be inspected visually for particulate matter and discoloration, prior to administration, whenever solution and container permit. The reconstituted solution is stable for 24 hours at 15° to 30° C. Any unused solution should be discarded. Solutions of reconstituted GEMZAR should not be refrigerated, as crystallization may occur.

Special Handling Instructions

Procedures for proper handling and disposal of anti-cancer drugs should be considered. Several guidelines on this subject have been published.

DOSAGE FORMS, COMPOSITION AND PACKAGING

GEMZAR is for intravenous use only.

Each 200 mg vial contains GEMZAR (gemcitabine) 200 mg (as the hydrochloride salt), mannitol 200 mg and sodium acetate 12.5 mg. Each 1 g vial contains gemcitabine 1 g (as the hydrochloride salt), mannitol 1 g, and sodium acetate 62.5 mg. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: gemcitabine hydrochloride

Chemical name: 2'-Deoxy-2',2'-difluorocytidine monohydrochloride (β -isomer)

Molecular formula and molecular mass: $C_9H_{11}F_2N_3O_4 \cdot HCl$ (299.66)

Structural formula:



Physicochemical properties:

- white to off-white solid
- soluble in water
- slightly soluble in methanol
- practically insoluble in ethanol and polar organic solvents
- the pH of a 1% aqueous solution is 2.5, and the pKa is 3.6

CLINICAL TRIALS

Pancreatic Cancer: Data from two clinical trials evaluated the use of GEMZAR in patients with locally advanced or metastatic pancreatic cancer. The first trial compared GEMZAR to 5-Fluorouracil (5-FU) in patients who had received no prior chemotherapy. A second trial studied the use of GEMZAR in pancreatic cancer patients previously treated with 5-FU or a 5-FU-containing regimen. In both studies, the first cycle of GEMZAR was administered intravenously at a dose of 1000 mg/m² over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitated holding a dose) followed by a week of rest from treatment with GEMZAR. Subsequent cycles consisted of injections once weekly for 3 consecutive weeks out of every 4 weeks.

The primary efficacy parameter in these studies was "clinical benefit response", which is a measure of clinical improvement based on analgesic consumption, pain intensity, performance status and weight change. Definitions for improvement in these variables were formulated prospectively during the design of the two trials. A patient was considered a clinical benefit responder if either:

- i) the patient showed a $\geq 50\%$ reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or a twenty point or greater improvement in performance status (Karnofsky Performance Scale) for a period of at least four consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as four consecutive weeks with either any increase in pain intensity or analgesic consumption or a 20 point decrease in performance status occurring during the first 12 weeks of therapy.

OR:

- ii) the patient was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain ($\geq 7\%$ increase maintained for ≥ 4 weeks) not due to fluid accumulation.

The first study was a multicenter (17 sites in US and Canada), prospective, single-blinded, two-arm, randomized, comparison of GEMZAR and 5-FU in patients with locally advanced or metastatic pancreatic cancer who had received no prior treatment with chemotherapy. 5-FU was administered intravenously at a weekly dose of 600 mg/m² for 30 minutes. The results from this randomized trial are shown in Table 8. Patients treated with GEMZAR had statistically significant increases in clinical benefit response, survival, and time to progressive disease compared to 5-FU. The Kaplan-Meier curve for survival is shown in Figure 1.

Table 8: GEMZAR Versus 5-FU in Pancreatic Cancer

	GEMZAR	5-FU	
Number of patients	63	63	
Male	34	34	
Female	29	29	
Median age	62 years	61 years	
Range	37 to 79	36 to 77	
Stage IV disease	71.4%	76.2%	
Baseline KPS ^a ≤70	69.8%	68.3%	
Clinical benefit response	23.8% (N ^c = 15)	4.8% (N = 3)	p = 0.0022
Survival			
Median	5.7 months	4.2 months	p = 0.0009
6-month probability ^b	(N = 30) 46%	(N = 19) 29%	
9-month probability ^b	(N = 14) 24%	(N = 4) 5%	
1-year probability ^b	(N = 9) 18%	(N = 2) 2%	
Range	0.2 to 18.6 months	0.4 to 15.1+ months	
95% C.I. of the median	4.7 to 6.9 months	3.1 to 5.1 months	
Time to Progressive Disease			
Median	2.3 months	0.9 months	p = 0.0002
Range	0.1+ to 9.4 months	0.1 to 12.0+ months	
95% C.I. of the median	1.9 to 3.4 months	0.9 to 1.1 months	

^a Karnofsky Performance Status

^b Kaplan-Meier estimates

^c N = number of patients

+ No progression at last visit; remained alive.

The p-value for clinical benefit response was calculated using the 2-sided test for difference in binomial proportions.

All other p-values were calculated using the Log Rank test for difference in overall time to an event.




Figure 1: Kaplan-Meier Survival Curve - GEMZAR Versus 5-FU in Pancreatic Cancer

Clinical benefit response was achieved by 15 patients treated with GEMZAR and 3 patients treated with 5-FU. One patient on the GEMZAR arm showed improvement in all three primary parameters (pain intensity, analgesic consumption, and performance status). Twelve patients on the GEMZAR arm and two patients on the 5-FU arm showed improvement in analgesic consumption and/or pain intensity with stable performance status. Two patients on the GEMZAR arm showed improvement in analgesic consumption or pain intensity with improvement in performance status. One patient on the 5-FU arm was stable with regard to pain intensity and analgesic consumption with improvement in performance status. No patient on either arm achieved a clinical benefit response based on weight gain.

The second trial was a multicenter (17 US and Canadian centers), open-label study of GEMZAR in 63 patients with advanced pancreatic cancer previously treated with 5-FU or a 5-FU-containing regimen. The study showed a clinical benefit response rate of 27% and median survival of 3.9 months.

Non-Small Cell Lung Cancer: Data from three randomized clinical studies (806 patients) support the use of GEMZAR, as a single agent or in combination with cisplatin, for the treatment of patients with locally advanced or metastatic NSCLC.

GEMZAR versus cisplatin plus etoposide: Single-agent GEMZAR was compared to the combination regimen of cisplatin plus etoposide in previously untreated patients with Stage IIIA, IIIB or IV NSCLC. Patients randomized to GEMZAR (n=72) received 1000 mg/m² on days 1, 8, and 15 of a 28-day cycle. Patients randomized to cisplatin plus etoposide (n=75) received 100 mg/m² of cisplatin on day 1 and 100 mg/m² of etoposide intravenously on days 1, 2 and 3 of each 28-day cycle. The primary end point was objective tumour response rate. Single-agent GEMZAR was as effective as the standard combination regimen of cisplatin

plus etoposide in the treatment of chemo-naïve NSCLC. The objective tumour response rate for GEMZAR was 17.9%, as compared to 15.3% for cisplatin plus etoposide, and there were no complete responses with either treatment. Median survival was estimated to be 6.6 months for GEMZAR patients and 7.6 months for cisplatin plus etoposide patients. The median time to progressive disease was 4.1 months in both treatment groups. Adverse events were less frequent with single-agent GEMZAR as compared to the combination regimen.

GEMZAR plus cisplatin versus cisplatin: This multicenter study enrolled 522 patients with inoperable Stage IIIA, IIIB, or IV NSCLC who had not received prior chemotherapy. GEMZAR 1000 mg/m² was administered on days 1, 8, and 15 of a twenty-eight day cycle with cisplatin 100 mg/m² administered on day 1 of each cycle. Single-agent cisplatin 100 mg/m² was administered on day 1 of each 28-day cycle. The primary end point was survival.

Efficacy data are summarized in Table 9, and the Kaplan-Meier survival curve is shown in Figure 2. Median survival time on the GEMZAR plus cisplatin arm was 9.1 months compared to 7.6 months on the single-agent cisplatin arm (Logrank p=0.0040, two-sided). Median time to disease progression was 5.6 months on the GEMZAR plus cisplatin arm compared to 3.7 months on the cisplatin arm (Logrank p=0.0013, two-sided). The objective response rate on the GEMZAR plus cisplatin arm was 30.4% compared to 11.1% with cisplatin (Fisher's Exact p<0.0001, two-sided). No differences between treatment arms with regard to median time to tumour response and duration of response were observed.




Figure 2 Kaplan-Meier Survival Curves - GEMZAR plus Cisplatin Versus Cisplatin in Non-Small Cell Lung Cancer

TABLE 9: GEMZAR plus Cisplatin in Non-Small Cell Lung Cancer

Efficacy Measure	Study JHEX			Study JHBR		
	Gemcitabine plus Cisplatin (N=260)	Cisplatin (N=262)	Significance	Gemcitabine plus Cisplatin (N=69)	Cisplatin plus Etoposide (N=64)	Significance
Tumour Response	30.4%	11.1%	Fisher's Exact Test ^a p<0.0001	40.6%	21.9%	Fisher's Exact Test p=0.0253
CR ^b	3 (1.2%)	1 (0.4%)		none	none	
PR	76 (29.2%)	28 (10.7%)		28 (40.6%)	14 (21.9%)	
PRNM	1 (0.4%)	1 (0.4%)		none	none	
SD	97 (37.3%)	111 (42.4%)		30 (43.5%)	28 (43.8%)	
PD	38 (14.6%)	86 (32.8%)		6 (8.7%)	14 (21.9%)	
Not Evaluable	20 (7.7%)	17 (6.5%)		1 (1.4%)	none	
Unknown	25 (9.6%)	18 (6.9%)	4 (5.8%)	8 (12.5%)		
Median Survival	9.1 months	7.6 months	Log-Rank p=0.0040 Wilcoxon p=0.0120	8.7 months	7.2 months	
6-month probability	69%	61%		72%	63%	
9-month probability	50%	42%		46%	42%	
1-year probability	39%	28%		30%	24%	
Median Time to Progressive Disease ^c	5.6 months	3.7 months	Log-Rank p=0.0013 Wilcoxon p=0.0003	6.9 months	4.3 months	Log-Rank p=0.0503 Wilcoxon p=0.0110
Median Time to Treatment Failure ^d	3.6 months	2.6 months	Log-Rank p=0.0026 Wilcoxon p=0.0040	4.1 months	3.1 months	Log-Rank p=0.2818 Wilcoxon p=0.0419
Median Time to Tumour Response ^e	1.9 months	1.8 months		1.4 months	1.5 months	
Duration of Tumour Response ^f	6.1 months	6.7 months		8.7 months	6.5 months	

^a Where a statistically significant difference was observed between treatment arms, the statistical test and p-value have been noted.

^b Abbreviations: CR, complete response; PR, partial response; PRNM, partial response non-measurable disease; SD, stable disease; PD, progressive disease.

^c The time from randomization until the time that the patient was classified as having progressive disease.

^d The time from randomization until the time that the patient discontinued from the study.

^e The number of months from randomization until tumour response was observed.

^f JHEX: the time from first objective status assessment of CR or PR to the first time of progression or death due to any cause. JHBR: for PRs, the time from randomization to the first time of progression or death due to any cause.

GEMZAR plus cisplatin versus etoposide plus cisplatin: A second, multicenter, study in Stage IIIB or IV NSCLC randomized 135 patients to GEMZAR 1250 mg/m² on days 1 and 8, and cisplatin 100 mg/m² on day 1 of a 21-day cycle or to etoposide 100 mg/m² I.V. on days 1, 2, and 3 and cisplatin 100 mg/m² on day 1 on a 21-day cycle (Table 9). The primary end point was objective tumour response rate.

The objective tumour response rate for GEMZAR plus cisplatin was significantly higher than that for cisplatin plus etoposide, 40.6% versus 21.9% (Fisher's Exact p=0.0253, two-sided). Median time to disease progression for the GEMZAR plus cisplatin arm was 6.9 months compared to 4.3 months on the etoposide plus cisplatin arm (Logrank p=0.0338, two-sided). There was no significant difference in survival between the two treatment arms (Logrank p=0.18, two-sided). The median survival was 8.7 months for the GEMZAR plus cisplatin arm versus 7.2 months for the etoposide plus cisplatin arm.

Bladder Cancer [Transitional Cell Carcinoma (TCC) of the Urothelium]—Data from a randomized, multicenter, phase III clinical trial (405 patients with Stage IV TCC of the bladder) and two phase II trials support the use of GEMZAR in combination with cisplatin for the first-line treatment of patients with Stage IV (locally advanced or metastatic) TCC of the bladder.

The primary objective of the randomized, phase III trial was to compare survival of patients with Stage IV (locally advanced or metastatic) TCC of the bladder treated with either GEMZAR plus cisplatin or methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). Patients had not received any prior systemic chemotherapy. Patients were randomized to one of the following intravenous treatments:

- i) Gemcitabine 1000 mg/m² on Days 1, 8, and 15, and cisplatin 70 mg/m² on Day 2 of each 28-day cycle,
OR:
- ii) Methotrexate 30 mg/m² on Days 1, 15, and 22, vinblastine 3 mg/m² on Days 2, 15, and 22, doxorubicin 30 mg/m² on Day 2, and cisplatin 70 mg/m² on Day 2 of each 28-day cycle.

The secondary endpoints of this study were one-year survival probability, time to disease progression, response rates, duration of response, toxicity profile, and changes in quality of life. Patient demographics are shown in Table 10.

The Kaplan-Meier survival curve is shown in Figure 3 and efficacy data are summarized in Table 11. Median survival time on the GEMZAR plus cisplatin arm was 12.8 months compared to 14.8 months on the MVAC arm (Logrank p=0.55). Median time to disease progression was 7.4 months on the GEMZAR plus cisplatin arm compared to 7.6 months on the MVAC arm (Logrank p=0.84). The overall response rate on the GEMZAR plus cisplatin arm was 49.4% compared to 45.7% on the MVAC arm (Chi-square p=0.51). Median duration of response was 9.6 months on the GEMZAR plus cisplatin arm compared to 10.7 months on the MVAC arm. Time to treatment failure on the GEMZAR plus cisplatin arm was 5.8 months vs. 4.6 months on the MVAC arm (Logrank p=0.139). Significantly more

patients on GEMZAR plus cisplatin had an increase in weight over baseline compared to MVAC patients (27% vs. 12% p=0.001).

GEMZAR plus cisplatin was better tolerated than MVAC based on the indicators of tolerability discussed below and shown in Table 12. GEMZAR plus cisplatin patients received a median of 6 cycles of treatment vs. a median of 4 cycles for MVAC patients. GEMZAR plus cisplatin patients experienced significantly fewer episodes of neutropenic sepsis than MVAC patients (1% vs. 11.9%, p<0.001). Patients on GEMZAR plus cisplatin experienced fewer episodes of febrile neutropenia resulting in hospitalization than did those on MVAC [9 hospital admissions (33 days) vs. 49 hospital admissions (272 days)]. Fewer GEMZAR plus cisplatin patients required colony-stimulating factors than did MVAC patients (6% vs. 20%). GEMZAR plus cisplatin patients experienced less Grade 3 and 4 alopecia than did MVAC patients (11% vs. 55%). Grade 3 and 4 nausea and vomiting occurred in approximately 20% of the patients in both treatment arms. Grade 3 and 4 mucositis occurred in 1% of GEMZAR plus cisplatin patients vs. 22% of MVAC patients (p= 0.001).

Table 10: Randomized Trial of Combination Therapy with GEMZAR plus Cisplatin vs. MVAC in TCC of the Bladder

Treatment Arm	GEMZAR plus cisplatin	MVAC
Number of patients (%)	N=203	N=202
Male	160 (79)	160 (79)
Female	43 (21)	42 (21)
Median age, years	63	63
Range	34 - 83	38 - 83
Baseline Disease (%)		
Stage IV	203 (100)	202 (100)
T4b only	16 (8)	19 (9)
Metastatic (M ₁)	141 (69)	127 (63)
Visceral	99 (49)	93 (46)
Baseline KPS ^a (%)		
60 to 80	90 (45)	92 (48)
90 to 100	109 (55)	101 (52)

^a Karnofsky Performance Scale




Figure 3: Kaplan-Meier Survival Curve in GEMZAR plus Cisplatin versus MVAC Bladder Cancer Study (N=405)

Table 11: Efficacy Data from Pivotal Randomized Trial of Combination Therapy with GEMZAR plus Cisplatin vs. MVAC in TCC of the Bladder

Treatment Arm	GEMZAR plus cisplatin	MVAC	
Survival	N=203	N=202	p = 0.55
Median, months	12.8	14.8	
(95% C.I.) months	12.0-15.3	13.2-17.2	
1 year survival probability (%)	56.9	62.4	
Time to Disease Progression			p = 0.84
Median, months	7.4	7.6	
(95% C.I.) months	6.0-8.1	6.7-9.1	
Tumour Response (%)	N = 164	N=151	p = 0.51 ^a
Overall	49.4	45.7	
Duration of Response			p = 0.48
Median, months	9.6	10.7	
Time to Treatment Failure			p = 0.14
Median, months	5.8	4.6	

^a p-value for tumour response was calculated using the 2-sided Pearson Chi-square test for difference in binomial proportions. All other p-values were calculated using the Log-rank test for difference in overall time to an event.

Table 12: Indicators of Tolerability from the Randomized Trial of GEMZAR plus Cisplatin versus MVAC

Treatment Arm (N)	GEMZAR plus cisplatin (203)	MVAC (202)	
Median cycles of therapy	6	4	
Total cycles of therapy	943	792	
Neutropenia (%)			
Grade 3	41	17	
Grade 4	30	65	
Neutropenic sepsis (%)	1	11.9	p<0.001
Febrile neutropenia			
Hospitalizations ^a	9	49	
Duration of stay ^b	33	272	
Colony-stimulating factors (%)	6	20	
Alopecia (%)			
Grades 3 and 4	11	55	
Mucositis (%)			
Grades 3 and 4	1	22	p= 0.001
Nausea/Vomiting			
Grades 3 and 4	22	21	

^a Patient admissions due to febrile neutropenia.

^b Days of hospitalization due to febrile neutropenia.

Quality of Life (QOL): QOL was measured using the EORTC QLQ-C30, which assessed physical and psychological functioning and symptoms related to cancer and its treatment. Both arms noted improvement in pain and emotional functioning. Fatigue worsened in the MVAC arm but did not change in the GEMZAR plus cisplatin arm. In all other scales, QOL was maintained in both treatment arms.

Additional Supporting Studies: A phase II nonrandomized trial using GEMZAR in combination with cisplatin in 46 patients with Stage IV (metastatic) TCC of the bladder who had not received treatment for metastatic disease supports the use of GEMZAR plus cisplatin as treatment for this disease. The regimen in this study was GEMZAR 1000 mg/m² on Days 1, 8 and 15 and cisplatin 75 mg/m² on Day 1 of each 28-day cycle. The first 11 patients received cisplatin 100 mg/m² on Day 1; however, Grade 3/4 neutropenia (100%) and thrombocytopenia (73%) in the 11 patients resulted in a dose reduction to 75 mg/m². In this study, the response rate was 41% and the median survival was 14.3 months. A second phase II [31 patients with Stage IV (locally advanced or metastatic) TCC of the bladder] trial used the same regimen as in the randomized trial. In this study the response rate was 57% and the median survival was 12.6 months. In both these trials, overall toxicities were similar to those seen in the randomized phase III trial.

Breast Cancer: Data from the pivotal study, JHQG (N=529), support the use of GEMZAR in combination with paclitaxel for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant anthracycline-based chemotherapy. In this multicentre, open-label, randomized Phase 3 study of metastatic breast cancer patients who have received prior adjuvant / neoadjuvant chemotherapy, 267 patients were randomly assigned to the GEMZAR plus paclitaxel arm and 262 patients were randomly assigned to the paclitaxel alone arm.

The study objectives were to compare overall survival, time to documented disease progression (TtDPD), progression-free survival (PFS), response rates, duration of response, and toxicities between patients treated with GEMZAR plus paclitaxel combination therapy and those treated with paclitaxel monotherapy.

The Kaplan-Meier plot of overall survival for randomized patients is shown in Figure 4, while the overall efficacy results of Study JHQG are summarized below and in Table 13:

- Survival analysis showed improvement in the GEMZAR plus paclitaxel arm compared with the paclitaxel alone arm, as demonstrated by a longer median survival (18.6 versus 15.8 months, with a hazard ratio of 0.817 (95% confidence interval [CI], 0.667 to 1.000, log-rank p=0.0489).
- Median time to documented progression of disease (TtDPD) was 5.4 months (95% CI 4.6 to 6.1 months) for patients on the GEMZAR plus paclitaxel arm and 3.5 months (95% CI 2.9 to 4.0 months) for patients on the paclitaxel alone arm.
- The GEMZAR plus paclitaxel arm demonstrated statistically significant improved PFS (5.3 months versus 3.5 months, p=0.0021) and response rate (39% versus 26%, p=0.0007) over the paclitaxel alone arm. There was no statistical significant difference in duration of response between treatment arms.




Figure 4: Kaplan-Meier Plot of Overall Survival in Randomized Patients, Study JHQQ.

Table 13: Efficacy Results of Pivotal Trial Study JHQG Supporting Combination Therapy of GEMZAR plus Paclitaxel in Patients with Metastatic Breast Cancer.

Efficacy Endpoint	Study JHQG	
	GEMZAR plus paclitaxel (N=267)	Paclitaxel alone (N=262)
Median Overall Survival ^a	18.6 months	15.8 months
95% CI	16.6 to 20.7 months	14.4 to 17.4 months
log-rank test	p=0.0489	
HR (95% CI); Wald Test	HR: 0.817 (0.667 to 1.000); p=0.495	
Median TtDPD ^b	5.4 months	3.5 months
95% CI	4.6 to 6.1 months	2.9 to 4.0 months
log-rank test	p=0.0013	
HR (95% CI); Wald test	HR: 0.734 (0.607 to 0.889); p=0.0015	
Median TtPD/PFS ^c	5.3 months PFS	3.5 months PFS
95% CI	4.4 to 5.9 months	2.8 to 4.0 months
log-rank test	p=0.0021	
HR (95% CI); Wald test	HR: 0.749 (0.621 to 0.903); p=0.0024	
Response rate—investigator-assessed	39% (105/267)	26% (67/262)
95% CI	34% to 45%	20% to 31%
number of patients with CR/PR/SD	18 CR /87 PR /90 SD	11 CR /56 PR /94 SD
z-test for normal approximation	p=0.0007	
Response rate—independently reviewed ^d	46% (90/198)	26% (47/184)
95% CI	39% to 52%	19% to 32%
number of patients with CR/PR/SD	9 CR /81 PR /71 SD	2 CR /45 PR /78 SD
z-test for normal approximation	p=0.00005	

^a The censoring rate for median overall survival was 31.6% for the GEMZAR plus paclitaxel arm and 25.9% for the paclitaxel alone arm.

^b The censoring rate for TtDPD was 23% for GEMZAR plus paclitaxel arm and 17% for the paclitaxel alone arm.

^c The censoring rate for PFS was 18% for GEMZAR plus paclitaxel arm and 14% for the paclitaxel alone arm.

^d Overall best study response was determined by independent review for 382 patients (198 GEMZAR plus paclitaxel arm, 184 paclitaxel alone arm).

Abbreviations: N = number of patients; TtDPD = time to documented progression of disease; CI = confidence interval; HR = hazard ratio; PFS = progression-free survival; CR = complete response; PR = partial response; SD = stable disease.

Other Clinical Studies

Dose-Range Studies: When GEMZAR was administered more frequently than once weekly or with infusions longer than 60 minutes, increased toxicity was observed. Results of a Phase 1 study of GEMZAR to assess the maximum tolerated dose (MTD) on a daily x 5 schedule showed that patients developed significant hypotension and severe flu-like symptoms that were intolerable at doses above 10 mg/m². The incidence and severity of these events were dose-related. Other Phase 1 studies using a twice-weekly schedule reached MTDs of only 65 mg/m² (30-minute infusion) and 150 mg/m² (5-minute bolus). The dose-limiting toxicities were thrombocytopenia and flu-like symptoms, particularly asthenia. In a Phase 1 study to assess the maximum tolerated infusion time, clinically significant toxicity, defined as myelosuppression, was seen with weekly doses of 300 mg/m² at or above a 270-minute infusion time. The half-life of gemcitabine is influenced by

the length of the infusion (see ACTION AND CLINICAL PHARMACOLOGY section) and the toxicity appears to be increased if GEMZAR is administered more frequently than once weekly or with infusions longer than 60 minutes (see WARNINGS AND PRECAUTIONS section).

DETAILED PHARMACOLOGY

Cellular Metabolism and Mechanisms of Action:

Gemcitabine exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and, under certain conditions, blocking the progression of cells through the G1/S-phase boundary. *In vitro* the cytotoxic action of gemcitabine is both concentration-dependent and time-dependent.

Gemcitabine (difluoro-deoxy-cytidine; dFdC) is metabolized intracellularly by nucleotide kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleotides. The cytotoxic action of gemcitabine appears to be due to inhibition of DNA synthesis by two actions of dFdCDP and dFdCTP. First, dFdCDP inhibits ribonucleotide reductase which is uniquely responsible for catalyzing the reactions that generate the deoxynucleotide triphosphates for DNA synthesis. Inhibition of this enzyme by dFdCDP causes a reduction in the concentrations of deoxynucleotides in general, and especially in that of dCTP. Second, dFdCTP competes with dCTP for incorporation into DNA. Likewise, a small amount of gemcitabine may also be incorporated into RNA. Thus, the reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA. DNA polymerase epsilon is essentially unable to remove gemcitabine and repair the growing DNA strands. After gemcitabine is incorporated into DNA, one additional nucleotide is added to the growing DNA strands. After this addition there is essentially a complete inhibition in further DNA synthesis (masked chain termination). After incorporation into DNA, gemcitabine appears to induce the programmed cellular death process known as apoptosis.

Anti-Tumour Activity:

In vivo:

In animal tumour models, the anti-tumour activity of gemcitabine is schedule-dependent. When administered daily gemcitabine causes significant animal lethality with very little anti-tumour activity. However, when an every third or fourth day dosing schedule is used gemcitabine can be given at non-lethal doses that have an excellent anti-tumour activity against a broad range of murine tumours. For example, at non-toxic doses gemcitabine inhibits by 95-100% the growth of the following subcutaneously growing murine tumours: X5563 plasma cellmyeloma, 6C3HED lymphosarcoma, CA-755 mammary adenocarcinoma and M5 ovarian carcinoma. Gemcitabine inhibits the growth of subcutaneously growing B16 melanoma in the range of 60 - 80%. Gemcitabine produces significant increases in the life span of mice bearing the leukaemia models P388 and L1210 in the range of 50 - 200%. Gemcitabine also inhibits the growth of P 1534J and Friend Leukaemia in the order of 90%.

Gemcitabine has anti-tumour activity against a broad spectrum of human tumours grown as xenografts in immunologically deficient mice. As with murine tumours, optimum anti-tumour activity is seen when gemcitabine is given on a staggered dosing schedule. Several studies have shown that gemcitabine, at non-toxic doses, inhibits by 90-100% the growth of the following human carcinoma xenografts: non-small cell lung, mammary, colon, gastric, pancreatic, ovarian and head and neck.

Gemcitabine demonstrated dose-dependent synergistic activity with cisplatin *in vitro*, and no effect of cisplatin on gemcitabine triphosphate accumulation or DNA double-strand breaks was observed. *In vivo*, gemcitabine showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. When tested against the CALU-6 human lung adenocarcinoma xenograft, gemcitabine plus cisplatin produced 80% tumour regression and 98% tumour growth inhibition, without toxicity, and was more effective than gemcitabine alone at preventing regrowth of this tumour. Gemcitabine was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to gemcitabine 4 hours before cisplatin produced the greatest interaction.

TOXICOLOGY

Repeat Dose Toxicity Studies:

In repeat dose studies of up to 6 month in duration in mice and dogs, the principal finding was haematopoietic suppression. These effects were related to the cytotoxic properties of the drug and were reversible when treatment was withdrawn. The degree of the effect was schedule and dose-dependent.

Carcinogenicity, Mutagenicity, and Fertility Studies:

Chromosomal damage, including chromatid breaks, has been produced by gemcitabine in *in vitro* studies. Gemcitabine caused a reversible, dose and schedule dependent hypospermatogenesis in male mice. Although animal studies have shown an effect of gemcitabine on male fertility, no effect has been seen on female fertility. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of gemcitabine. Gemcitabine induced forward mutations *in vitro* in a mouse lymphoma (L51178Y) assay and was clastogenic in an *in vivo* mouse micronucleus assay. Gemcitabine was negative when tested using the Ames, *in vivo* sister chromatid exchange, and *in vitro* chromosomal aberration assays, and did not cause unscheduled DNA synthesis *in vitro*. Gemcitabine I.P. doses of 0.5 mg/kg/day (about 1/700 the human dose on a mg/m² basis) in male mice had an effect on fertility with moderate to severe hypospermatogenesis, decreased fertility, and decreased implantations. In female mice fertility was not affected but, maternal toxicities were observed at 1.5 mg/kg/day I.V. (about 1/200 the human dose on a mg/m² basis) and fetotoxicity or embryoletality was observed at 0.25 mg/kg/day I.V. (about 1/1300 the human dose on a mg/m² basis).

The results of the toxicology studies involving gemcitabine are presented in Tables 14 to 17.

Table 14: Results Of Acute Toxicity Studies With Gemcitabine Hydrochloride

Species, Strain	No/Sex/Group; Age	Doses (mg/kg/day)	Route of Administration	Duration of Observation	Parameters Evaluated	Observations
Mouse, ICR	5/sex; 4-5 wk	0, 500	IV ^a	2 wk	Mortality, clin obs., body wt., gross pathology.	Poor grooming; ↓body wt. gain; leg weakness & clonic convulsion in control & treated mice; MLD>500 mg/kg.
Rat, Fischer 344	5 F; 8-9 wk	0, 16, 33, 70, 160	IV ^a	2 wk	Mortality, clin obs., body wt., gross pathology.	Poor grooming, leg weakness; hypoactivity, diarrhea, ataxia, chromorrhinorrhea, swollen face, chromadacryorrhea, emaciation, tremors, clonic convulsions, dark urine, pale eyes; MLD=64 mg/kg.
Mouse, ICR	5/sex; 4-5 wk	0, 500	IV ^c	2 wk	Mortality, clin obs., body wt., gross pathology.	Leg weakness, hair loss; MLD>500 mg/kg.
Rat, Fischer	5F; 8-9 wk	0, 16, 33, 45, 70, 90, 160	IV ^c	2 wk	Mortality, clin. obs., body wt., gross pathology.	Poor grooming, leg weakness, hypoactivity, soft stool, diarrhea, excessive hair loss, emaciation, chromodacryorrhea, ptosis, pale eyes; MLD=236 mg/kg.
Dog, Beagle	1/sex; 8-10 mo	3, 12, 18, 24	IV ^c	2 wk	Mortality, clin. obs., body wt., food consumption, hematology, clinical chem.	Soft or mucoid stools, reversible neutropenia; MLD>24 mg/kg.

^am-cresol/phenol diluent

^bMLD=Median Lethal Dose

^cSaline Diluent

Table 15: Results Of Subchronic and Chronic Toxicity Studies With Gemcitabine Hydrochloride

Species, Strain	No./Sex/Group; Age	Doses (mg/kg)	Route of Administration	Duration of Treatment	Parameters Evaluated	Observations
Subchronic Studies						
Dog, Beagle	4/sex; 7-9 mo.	0, 0.1 (daily) 1.5 (twice wkly)	IV	3 mo	Survival; clin. obs.; physical & ophthalmic exams; body wt.; food consumption; hematol.; clinical chem.; urinalysis; organ wt.; pathology.	Abnormal stools; reversible mild to moderate ↓leucocytes & platelets in 1.5 mg/kg reversible minimal ↓erythrocyte count in 0.1 mg/kg group; hypoplasia of thymus & testes & ↓postmitomyeloid pool in bone marrow in 1.5 mg/kg group.
Mouse, B6C3F ₁	15/sex; 5-6 wk	0, 1 (daily); 5, 20 (2 X wkly) 40 (once weekly)	IP	3 mo	Survival, clin. obs.; body wt.; hematology; clinical chem.; organ wt.; pathology.	↓hemoglobin, PCV, erythrocyte & leukocyte counts in 1 mg/kg group; ↑spleen & ↓testes wt.; splenic erythropoiesis & spermatogenesis.
Chronic Studies						
Mouse, CD-1	30/sex; 5-6 wk	0, 0.5 (daily); 5 (twice weekly); 40 (once weekly)	IP	6 mo; 2 mo recovery	Survival; clin. obs.; body wt.; hematol.; clin. chem.; organ wt.; pathology.	Mortality (3), ↓body wt. & wt. gain; reversible ↓erythrocyte & lymphocyte counts, reversible ↑BUN & ↓total protein, ↓testes wt., ↑spleen wt., splenic erythropoiesis, & lymphoid hypoplasia in 0.5 mg/kg group; hypospermatogenesis in all treated males partially reversible.
Mouse, CD-1	15/sex; 5-6 wk	0, 0.006, 0.06 0.3 (daily)	IP	6 mo; 6-wk recovery	Survival; clin. obs.; body wt.; food consumption; hematol.; clin. chem.; urinalysis; organ wt.; pathology.	Slight ↓body wt.; reversible ↓erythrocyte count, ↓testes wt.; ↑spleen wt.; hypospermatogenesis in 0.3 mg/kg group; spleen & testes changes partially reversible.
Dog Beagle	3-4/sex; 7-9 months	0, 0.004, 0.04, 0.2 (daily); 0.3 (once weekly)	IV	6 mo; 6-wk recovery	Survival; clin. obs.; body wt.; food consumption; ophthalmic & physical exams; ECG; hematol.; clin. chem.; urinalysis; organ wt.; pathology.	Reversible slight ↓erythrocyte count in 0.2 mg/kg group; slight ↓lymphocyte & neutrophil counts in 0.2 & 0.3 mg/kg groups.

Table 16: Results Of Reproduction Studies With Gemcitabine Hydrochloride

Species, Strain	No./Sex/ Group; Age	Doses (mg/kg)	Route of administration	Duration of Treatment	Parameters Evaluated	Observations
Mouse, B6C3F ₁	20 M; 5 wk	0, 0.05, 0.5 (daily); 3.5, 10 (weekly)	IP	10 wk prior to mating, throughout mating	Survival; clin. obs.; body wt.; food cons.; mating performance; fertility; resorptions; fetal parameters; testes wt. & histopath.	↓fertility, implantations (0.5 mg/kg daily) ↓testicular wt., hypospermatogenesis (0.5 mg/kg/day & 3.5 & 10 mg/kg/week).
Mouse, CD-1	25 F; 9 wk	0, 0.5, 0.25, 1.5 (daily)	IV	2 wk prior to mating, through Gestation Day 6	Survival; clin. obs; body wt.; food cons; mating performance; fertility; resorptions; fetal parameters; hematology; organ wt.	↓fetal viability; ↓fetal wt.; ↑%fetal runts; slight ↑PCV; hemoglobin, MCV, MCH; ↑spleen wt. (1.5 mg/kg/day).
Mouse, CD-1	25 F (Teratology) 20F (Postnatal); adult, virgin	0, 0.05, 0.25, 1.5 (daily)	IV	Gestation Days 6-15	Survival; clin. obs.; body wt.; food cons.; reproduction (F ₀ & F ₁); fetal parameters; progeny measurements (F ₀ & F ₁); F ₀ preweaning & F ₁ postweaning behavior; hematology F ₀ pathology (F ₀ & F ₁ generations).	↑vaginal discharge & abortions; ↓body wt., food cons.; (1.5 mg/kg/day). ↑spleen wt.; (0.05, 0.25 & 1.5 mg/kg/day). ↓liver wt.; ↑thymus wts.; ↓fetal wt.; ↓fetal malformations (1.5 mg/kg). ↓liveborn progeny, ↓progeny survival; ↓progeny wt. (1.5 mg/kg/day). ↓relative ovary wt. in all F ₁ groups. ↓startle reactivity in F ₁ males (0.05 & 1.5 mg/kg/day groups). ↑MCV, MCH (0.25 & 1.5 mg/kg/day).
Mouse, CD-1	25 F; adult, virgin	0, 0.05, 0.1, 0.25, 1.5 (daily)	IV	Gestation Day 15- Postpartum Day 20	Survival; clin. obs.; body wt.; food cons.; organ wts. (F ₀ & F ₁); reproduction & progeny measurements (F ₀ & F ₁); preweaning & postweaning behavior; hematology (F ₀); pathology (F ₀ & F ₁).	↓fetal viability, ↓fetal wt.; ↑malformations & deviations (0.1 mg/kg/day), ↓erythrocytes, hemoglobin, PCV (0.1 mg/kg/day).
Rabbit, New Zealand, White	20 F; mated adult	0, 0.0015, 0.005, 0.1 (daily)	IV	Gestation Days 6-18	Survival; clin. obs.; body wt.; food cons.; hematology; fetal viability, fetal wt., morphology.	↓fetal viability, ↓fetal wt., ↑malformations & deviations (0.1 mg/kg/day); ↓erythrocytes, hemoglobin, PCV (0.1 mg/kg/day).

Table 17: Results Of Mutagenicity Studies With Gemcitabine Hydrochloride

Type of Study	Species, Cells	Route of Administration	Doses/ Concentrations	Results
Ames	<i>Salmonella typhimurium</i> , <i>Escherichia coli</i>	Not applicable	125 to 5000 µg/plate	Negative nonactivated & activated
Unscheduled DNA	Adult rat hepatocytes	Not applicable	0.5 to 1000 µg/ml	Negative
Forward mutation at thymidine kinase locus	L5178Y TK [±] -mouse lymphoma	Not applicable	0.001 to 0.06 µg/ml	Positive non activated & with metabolic activation
Sister chromatid exchange in bone marrow	Chinese hamster	Intraperitoneal	3.125 to 50 mg/kg	Negative
Chromosome aberration	Chinese hamster ovary	Not applicable	0.005 to 0.03 µg/ml, 0.04 to 0.1 µg/ml	Negative nonactivated; with metabolic activation
Micronucleus	Mouse, bone marrow	Intravenous	0, 0.1875, 0.375, 0.75 mg/kg	Positive

REFERENCES

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adarns T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. *J Clin Oncol*. 1991;9:491-498.
2. Advanced Ovarian Cancer Trialists Group. Chemotherapy in ovarian cancer: an overview of randomised clinical trials. *Br Med J* 1991; 303: 884 - 893.
3. Aisner J, Weinberg V, Perloff M et al. Chemotherapy versus chemo-immunotherapy (CAF v CAFVP v CMF each \pm MER) for metastatic carcinoma of the breast: a CALBG study. *J Clin Oncol* 1987; 5: 1523 -1533.
4. Andersen JS, Burris HA, Casper E, Clayman M, Green M, Nelson RL, Portenoy R, Rothenberg M, Tarassoff PG, Von Hoff DD. Development of a new system for assessing Clinical benefits for patients with advanced pancreatic cancer (meeting abstract). *Proc Annu Meet Am Soc Clin Oncol*. 1994; 13: A1600.
5. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI et al. Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of therapy. *J Clin Oncol* 1999;17(10):3173-3181.
6. Bishop JF, Dewar J, Toner C, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. *J Clin Oncol* 1999;17(8):2355-2364.
7. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, Blatter J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. *British Journal of Cancer* 1996; 73: 101-105.
8. Cartei G, Cartei F, Cantone A, Causarano D, Genco G, Tobaldin A et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for the treatment of metastatic non-small cell lung cancer. *J Natl Cancer Inst* 1993; 85: 794 - 800.
9. Casper ES, Green MR, Kelsen DP, Hellan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. *Invest New Drugs* 1994; 12: 29-34.
10. Coates A, GebSKI V, Bishop JF et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. *N Engl J Med* 1987; 317: 1490 -1495.
11. Cormier Y, Bergeron D, Laforge J, et al. Benefit of polychemotherapy in advanced non-small cell lung bronchogenic carcinoma. *Cancer* 1982; 50: 845 - 849.
12. Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. *Br J Cancer* 1988; 58: 359 - 361.
13. Cullen MH. The MIC regimen in non-small cell lung cancer. *Lung Cancer* 1993; 9 (suppl 2): 81- 89.

14. Cummings FJ, Gelman R, Horton J. Comparison of CAF versus CMFP in metastatic breast cancer analysis of prognostic factors. *J Clin Oncol* 1985; 3: 932 - 940.
15. DeVita VT Jr, Hellman S, Rosenberg SA, eds. *Cancer: Principles and Practice of Oncology*. Philadelphia, Pa: JB Lippincott Co; 1993;1:673.
16. Donnadieu N, Paesmans M, Sculier J-P. Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. *Lung Cancer*. 1991;7:243-252.
17. Evans WK. Management of metastatic non-small-cell lung cancer and a consideration of cost. *Chest*. 1993;103(1):68S-71S.
18. Evans WK. Rationale for the treatment of non-small cell lung cancer. *Lung Cancer*. 1993;9(suppl. 2):S5-S14.
19. Genot JY, Tubiana-Hulin M, Tubiana-Mathieu N, Piperno-Neumann S. Gemcitabine and Paclitaxel in Metastatic Breast Cancer: a Phase 2 Study in the First Line Setting. *Proc ASCO* 2002. 21(Part 2):44b.
20. Ginsberg RJ, Gris MG & Armstrong JG. in: *Cancer: Principles and Practice of Oncology*, Fourth Edition. Ed: Vincent De Vita Jr, Samuel Hellmann, Steven A Rosenberg. Philadelphia, JB Lippincott Co 1993; 673 - 723.
21. Green MR. Gemcitabine: We've reached the end of the beginning. *Semin Oncol* 1996; 23(5 SUPPL. 10): 99-100.
22. Grindey G et al. Cytotoxicity and antitumor activity of 2',2' difluorodeoxycytidine (gemcitabine). *Cancer Invest*. 1990;8:313
23. Grunewald R, Abbruzzese JL, Tarassof P, Plunkett W. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. *Cancer Chemother Pharmacol*. 1991 ,27:258-262.
24. Hanks GE, Myers CE, Scardino PT. Cancer of the Prostate. in: *Cancer: Principles and Practice of Oncology*, Fourth Edition. Ed: Vincent De Vita Jr, Samuel Hellmann, Steven A Rosenberg. Philadelphia, JB Lippincott Co 1993; 1073 -1113.
25. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. *Br J Cancer* 1989; 60: 764 - 766.
26. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-β-D-Arabinofuranosylcytosine. *Cancer Res*. 1988;48:4024-4031.
27. Heinemann V, Wilke H, Possinger K, Mergenthaler K, Clemens M, König HJ, Illiger HJ, Blatter J, Schallhorn A, Fink U. Gemcitabine and cisplatin: combination treatment for advanced and metastatic pancreatic carcinoma (Meeting abstract). *Proc Annu Meet Am Soc Clin Oncol* 1996; 15: A623.
28. Ihde DC, Minna JD. Non small cell lung cancer. Part II. Treatment. In: Haskell CM, ed. *Current Problems in Cancer*. St. Louis, MO: Mosby-Year Book Inc; 1991;109-153.
29. Ihde DC. Chemotherapy of lung cancer. *N Engl J Med* 1992; 327: 1434 -1441.

30. Ihde DC, Pass HI, and Glatstein EJ. Small Cell Lung Cancer. in: Cancer Principles and Practice of Oncology, Fourth Edition. Ed: Vincent De Vita Jr, Samuel Hellmann, Steven A Rosenberg. Philadelphia, JB Lippincott Co 1993; 732 - 736.
31. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. *J Clin Oncol*. 1990;8:1301-1309.
32. Jensen OM, Esteve J, Moller H, Renard H. Cancer in the European community and its member states. *Eur J Cancer*. 1990;26:1167-1256.
33. Lawrence TS, Chang EY, Hahn TM, Jertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. *Int J Radiat Oncol Biol Phys* 1996;34(4):867-872.
34. Le Chevalier T, Scagliotti G, Natale R, et al. 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. *Lung Cancer* 47:69-80
35. Lenzi R, Fossella FV, Lee JS. Systemic treatment of non-small cell lung cancer. *Comp. Ther.* 1992;18:27-30.
36. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. 1992. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative study. *J Clin Oncol* 10(7): 1066-1073.
37. Moore M. Activity of gemcitabine in patients with advanced pancreatic carcinoma: a review. *Cancer* 1996; 78(3 SUPPL):633-638.
38. Moore M, Andersen J, Burris H, Tarasoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R. A randomized trial of gemcitabine (gem) versus 5FU as first-line therapy in advanced pancreatic cancer (meeting abstract). *Proc Annu Meet Am Soc Clin Oncol* 1995; 14:A473.
39. Nabholz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. *J Clin Oncol* 1996; 14(6):1858-1867.
40. Niyikiza C, Anderson JS, Tarasoff PG, Rothenberg ML, Seitz DE, Nelson RL. Prognostic factors in a randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer and in pancreatic cancer patients failing 5-FU who receive gemcitabine (GEM) as a palliative therapy. *Proc Am Soc Clin Oncol* 1996; 15(32): A506.
41. Osoba D, Rusthoven JJ, Turnbull KA, Evans WK, Shepherd FA. Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer. *J Clin Oncol*. 1985;1 1: 1478-1485.
42. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as firstline single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer randomized study with cross-over. *J Clin Oncol* 2000;18(4):724-733.
43. Parkin DM, Pisani P, Ferlay J. 1999. Global cancer statistics. *CA Cancer J Clin* 49(1):33-64.
44. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. 1995.

- Interaction between cisplatin and gemcitabine in vitro and in vivo. *Semin Oncol* 22 (4 Suppl 11):72-79.
45. Plunkett, et al. Increased cytotoxicity and therapeutic activity of 2',2' difluorodeoxycytidine (dFdC) over cytosine arabinoside (araC) in L 1210 leukemia. *Proc Am Assoc Cancer Res.* 1988;29:352.
 46. Poplin E, Thompson B, Whitacre M, Alsner J. Small cell carcinoma of the lung: influence of age on treatment outcome. *Cancer Treat Reports.* 1987;71:291-296.
 47. Rapp E, Pater J, Willan A et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multicenter randomized trial. *J Clin Oncol* 1988; 6: 633 - 641.
 48. Rothenberg ML. New developments in chemotherapy for patients with advanced pancreatic cancer. *Oncology* 1996; 10(9 SUPPL.): 18-22.
 49. Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma *Cancer* 1996; 78 (3SUPPL.) 627-632.
 50. Rothenberg ML, Moore MJ, Cripps MC, Anderseen JS, Portenoy RK, Burris HA, 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo A-M., Von Hoff DD. A phase II trial of gemcitabine in patients with 5-fu-refractory pancreas cancer. *Ann Oncol* 1996; 7(4): 347-353.
 51. Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. A randomised trial of the four most active regimens for metastatic non-small cell lung cancer. *J Clin Oncol* 1986; 4: 14 - 22.
 52. Sandler AB, Buzaid AC. Lung cancer: a review of current therapeutic modalities. *Lung* 1992; 170: 249 - 265.
 53. Samet J, Hunt WC, Key C, Humble CG, Goodwin JS. Choice of cancer therapy varies with age of patient. *JAAC.* 1986; 255: 3385-3390.
 54. Scagliotti GV, De Marinis F, Rinaldi M, et al. 2002. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. *J Clin Oncol.* 20: 4285-4291.
 55. Scher HI, Bahnson R, Cohen S, et al. 1998. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. *Oncology* 12(7A):225-271.
 56. Schnall SF, Macdonald JS. Chemotherapy of adenocarcinoma of the pancreas. *Semin Oncol.* 1996; 23(2): 220-228.
 57. Shewach DS, Lawrence TS. Radiosensitization of human solid tumor cell lines with gemcitabine. *Semin Oncol* 1996; 23 (5 SUPPL 10): 65-71.
 58. Skarin A. Diagnosis in Oncology. *Journal of Clinical Oncology* 2000; 18(3):693-698.
 59. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. *J Clin Oncol* 1999;17(11):3403-3411.
 60. Sorensen JB. *Prognosis and Prognostic Factors in Adenocarcinoma of the Lung.* Kobenhavn:

Laegeforeningens Forlag; 1992.

61. Souhami RL and Law K. Longevity in small cell lung cancer. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. *Br J Cancer* 1990; 61: 584 - 589.
62. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bemard JP. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. *Lancet*. 1993; 342: 19-21.
63. Splinter TAW. Chemotherapy in advanced non-small cell lung cancer. *Eur J Cancer* 1990; 26: 1093 -1099.
64. Sternberg CN, Yagoda A, Scher HI, et al. 1989. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelial: efficacy and patterns of response and relapse. *Cancer* 64(12):2448-2458.
65. Tempero M, Capadano M, Tarassoff P. Dose escalation of gemcitabine in previously untreated patients with pancreatic adenocarcinoma (meeting abstract). *Proc Annu Meet Am Soc Clin Oncol* 1994; 13: A660.
66. Von Hoff DD. Gemcitabine: a case study for clinical benefit. *Semin Oncol* 1996; 23(5 SUPPL. 10): 1-2.
67. Winer EP, Morrow M, Osborne CK, et al. Malignant tumours of the breast. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. *Cancer, principles & Practice of oncology*. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins. 2001; P1651-1717.
68. World Health Organization. Handbook for reporting results of cancer treatment. WHO offset publications no. 48, Geneva 1979.

PART III: CONSUMER INFORMATION

GEMZAR[®]

Gemcitabine Hydrochloride for Injection

This leaflet is part III of a three-part "Product Monograph" published when GEMZAR was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about GEMZAR. Contact your doctor or nurse if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:

GEMZAR is an approved chemotherapy for treatment of:

- Non-small cell lung cancer (NSCLC), alone or in combination with another medication
- Pancreatic Cancer
- Bladder Cancer, in combination with another medication
- Breast Cancer, in combination with another medication

What it does:

GEMZAR is a chemotherapy that works through disrupting the cells ability to divide or grow. Chemotherapies are active in both healthy and cancer cells. However, cancer cells are known to divide or grow at a faster rate than most healthy cells making chemotherapies such as GEMZAR effective in the treatment of various cancers. While the time it takes to see if GEMZAR shrinks your cancer varies from person to person, your doctor will ask you if you are feeling better and will perform regularly scheduled examinations and x-rays to determine if GEMZAR has been effective.

When it should not be used:

Do not take GEMZAR if you have had an allergic or sensitivity reaction to this drug or any of its ingredients (see "What the important nonmedicinal ingredients are" section of this leaflet).

What the medicinal ingredient is:

Gemcitabine hydrochloride

What the important nonmedicinal ingredients are:

Mannitol, sodium acetate

What dosage forms it comes in:

GEMZAR is available in 200 mg and 1 g vials.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- **GEMZAR should only be prescribed by physicians experienced with delivery of chemotherapy**
- **GEMZAR is intended for intravenous use only**
- **GEMZAR infusion times longer than 60 minutes and given more often than once per week are known to increase negative side effects**
- **As with other chemotherapies, there is a risk of side effects, sometimes severe, with GEMZAR therapy**
- **GEMZAR routinely leads to a fall in blood counts which, if severe can lead to an increased risk of infection and bleeding**
- **GEMZAR has been associated with a type of pneumonia that can be quite severe in less than 1 in 1000 patients and less severe in less than 1 in 100 patients.**

BEFORE you receive GEMZAR talk to your doctor if:

- You have had an allergic reaction to any chemotherapy or have been treated with any chemotherapy in the past
- You are pregnant, plan on becoming pregnant, or are currently breast feeding
- You have liver or kidney problems, or a bone marrow disorder

INTERACTIONS WITH THIS MEDICATION

GEMZAR is known to increase your body's sensitivity to radiation therapy.

It is very important to tell your doctor about any medications you may be taking, including over-the-counter drugs, such as Aspirin[®] (acetylsalicylic acid), vitamins, and other pain relievers. Be sure to check with your doctor before taking any medications on your own.

PROPER USE OF THIS MEDICATION

Usual dose:

Your doctor will develop a GEMZAR treatment plan based on your needs. You are encouraged to discuss your treatment plan with your doctor. There are many points your doctor will consider when selecting the appropriate treatment plan for you. Your doctor may recommend skipping a dose based upon your response to GEMZAR.

Overdose:

GEMZAR will be given under the supervision of a qualified physician. Any overdose should be managed by a qualified physician experienced in the use of anticancer agents.

Missed Dose:

Contact your physician immediately for further instructions.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

In clinical studies of GEMZAR, side effects were generally manageable. Side effects significant enough to cause your treatment to be stopped occurred in about 10% of all patients. Less than 1% of patients stopped therapy due to any one side effect. Most side effects were reversible and can be managed by either a delay in your treatment, a reduction of the dose of chemotherapy or both. Therefore it is important for you to know about common side effects and for you to communicate any suspected side effects to your doctor.

You should discuss possible side effects with your doctor before beginning GEMZAR therapy and at any time you think you may be experiencing a side effect. For a list of possible side effects see the “Call Your Doctor or Nurse If You Experience” section and Serious Side Effects Table below.

In clinical studies of GEMZAR, the most common reason for dosage adjustments was low blood counts. About two thirds of patients had low blood counts. In about one fourth of patients, decreases in blood counts were severe. For more information speak with your doctor and see section below on Low Blood Counts.

Shortness of breath may develop or worsen during treatment due to disease progression or in rare cases, due to a direct effect of the drug. If this occurs, patients should inform their treating doctor immediately of the developing or worsening of shortness of breath.

Nausea and vomiting were the most common side effects in clinical studies of GEMZAR. About two thirds of patients experienced nausea and vomiting, which were usually mild to moderate. Other common side effects included fever, swelling, rash, and flu-like symptoms.

In rare cases, GEMZAR may affect your liver, especially if you have liver metastases (spreading of cancer) or a medical history of hepatitis (inflammation of the liver), alcoholism or liver cirrhosis (liver disease). Follow your doctor’s instructions on having periodic blood work to check your liver.

In rare cases, GEMZAR may affect your kidney, especially if your kidney function is not normal. Follow your doctor’s instructions on having periodic blood work to check your kidneys.

Low Blood Counts:

Chemotherapy drugs often affect the blood cells, which means that temporary changes in their counts may occur. These effects may be more common in patients older than 65 and in women. Blood tests will be done before each dose of GEMZAR to monitor your blood counts.

If your doctor notices changes in your blood counts, follow their advice, which may include:

White Blood Count:

- if your white blood count becomes low, you may have trouble fighting infections
- stay out of crowds and away from people with colds or other illnesses
- call your doctor if you develop a temperature over 38°C
- ensure regular mouth care to reduce chance of infection

Red Blood Count:

- if your red blood count becomes low, you may feel tired or weak. If it becomes too low, your doctor may recommend a red blood cell transfusion
- rest as much as you need to
- try to eat a well balanced diet

Platelet Count:

- if your platelet count becomes low, your blood may not clot as fast as usual, and bleeding or bruising may occur. Sometimes, a blood transfusion is given if platelet counts drop very low
- try to avoid getting cuts, bumps, or bruises (for example avoid contact sport and use an electric razor)
- since acetylsalicylic acid can affect your platelets, you should avoid taking acetylsalicylic acid while you are receiving chemotherapy, unless your doctor advises otherwise

Call Your Doctor or Nurse If You Experience:

- any unusual bruising or bleeding
- any pain around an infusion site
- a sore mouth or throat
- prolonged or uncomfortable swelling
- severe diarrhea, meaning three or more watery bowel movements per day, lasting more than 24 hours
- severe constipation for three days that has not been relieved by laxatives
- numbness or tingling in your hands or feet
- vomiting for more than 24 hours after your treatment
- any changes in your skin, especially rash or potential allergic skin reactions
- see Also Serious Side Effects Table below

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect		Talk with your doctor or nurse	
		Only if severe	In all cases
Very Common	Diarrhea		✓
	Swelling		✓
	Vomiting	✓	
Common	Body temperature over 38 °C or shaking chills		✓
	Fatigue	✓	
Uncommon	Shortness of breath		✓
Very Rare	Skin reactions including blistering		✓

This is not a complete list of side effects. For any unexpected effects while taking GEMZAR, contact your doctor or nurse.

HOW TO STORE IT

Handling and storage of GEMZAR is restricted to qualified healthcare professionals.

Keep out of reach of children.

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Health Canada by:

toll-free telephone: 866-234-2345

toll-free fax 866-678-6789

By email: cadrm@hc-sc.gc.ca

By regular mail:

Canadian Adverse Drug Reaction Monitoring Program (CADRMP)

Health Canada

Address Locator: 0201C2

Ottawa, ON K1A 1B9

NOTE: Before contacting Health Canada, you should contact your physician or pharmacist.

MORE INFORMATION

GEMZAR is manufactured by: Eli Lilly Canada Inc.

This leaflet was prepared by Eli Lilly Canada Inc., Toronto Ontario, M1N 2E8.

This leaflet plus the full product monograph, prepared for health professionals, can be obtained by contacting Eli Lilly Canada Inc., at: 1-888-545-5972 or visit the website at www.lilly.ca

For more information, please contact your healthcare professionals or pharmacist first, or Eli Lilly Canada Inc.

Last revised: February 02, 2006